Liquid pharmaceutical composition

专利摘要:
The invention relates to novel liquid pharmaceutical compositions of adalimumab which include adalimumab or a biosimilar agent thereof, a histidine buffer agent such as histidine (or a histidine buffer system such as histidine / imidiazolium histidine) and a sugar stabilizer such as trehalose. Such a combination of constituents provides formulations with a stability (e.g., by storage or exposures to loads) that are comparable to or improved from those known in the art and with fewer constituents. Such advances will promote the availability of adalimumab treatments at a lower cost and extend the shelf life of pre-filled dispensing devices (eg pre-filled syringes), thus reducing unnecessary waste of the drug.
公开号:DK201800071U1
申请号:DK201800071U
申请日:2018-09-07
公开日:2018-12-05
发明作者:Rinaldi Gianluca；FRATARCANGELI Silvia；Del Rio Alessandra
申请人:Fresenius Kabi Deutschland Gmbh；
IPC主号:

专利说明:

( ¹⁹ ) DENMARK (10)
DK 201800071 Y4
(12)
UTILITY MODEL WRITING
Changed registered utility model with testing
Patent and Trademark Office lnt.CI .: A61K 9/00 (2006.01) A61K 47/26 (2006.01) A61K 38/00 (2006.01)
Application Number: BA 2018 00071
Filing Date: 2018-09-07
Running Day: 2015-05-15
Aim. available: 2018-09-07
Registration bkg. and Published: 2018-12-13
Reg. is a branch of European Pat. No. EP15724974.9
Priority:
2014-05-23 EP 14169754
Use Model Holder:
Fresenius Kabi Deutschland GmbH, Else-Kröner-Strasse 1 61352 Bad Homburg, Germany
produces:
Gianluca Rinaldi, Via Silvestrini 9 00015 Monterotondo (RM), Italy
Silvia Fratarcangeli, C.so Risorgimento 3 03024 Ceprano (FR), Italy
Alessandra Del Rio, Via lldebrando Vivanti 108 00144 Roma (RM), Italy
Clerk:
AWA Denmark A / S, Strandgade 56.1401 Copenhagen K, Denmark
Title: Liquid pharmaceutical composition
Relevant publications:
WO 2011104381 A2
WO 2014039903 A2
WO 2013186230 A1
Summary:
The invention relates to novel liquid pharmaceutical compositions of adalimumab which include adalimumab or a biosimilar agent thereof, a histidine buffer agent such as histidine (or a histidine buffer system such as histidine and citrate), and a sugar stabilizer in particular amounts. Such a combination of constituents provides formulations with a stability (e.g., by storage or exposures to loads) that are comparable to or improved from those known in the art and with fewer constituents. Such advances will promote the availability of adalimumab treatments at lower costs and extend the shelf life of pre-filled dispensing devices (e.g. pre-filled syringes), thus reducing unnecessary waste of the drug.
To be continued...
DK 201800071 Y4
DK 201800071 Y4
Introduction
The production relates to a novel protein formulation. In particular, the preparation relates to a liquid pharmaceutical composition of adalimumab, a kit containing the composition, and a package containing the composition.
Background
Treatment of tumor necrosis factor-alpha (TNF-α) -related autoimmune disease such as rheumatoid arthritis, psoriasis and other autoimmune diseases has been achieved using FDA-approved drugs such as Adalimumab (HUMIRA®, Abbott Corporation). Adalimumab is a human monoclonal antibody that inhibits human TNF-α activity, preventing activation of TNF receptors, thereby downregulating inflammatory responses associated with autoimmune diseases. Approved medical indications for Adalimumab include arthritis rheumatoid, psoriatic arthritis, Bechterew's disease, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and arthritis.
Adalimumab is generally administered to a patient via subcutaneous injection, and is thus administered in liquid form, typically in packs such as vials, pre-filled syringes or pre-filled pen devices. Commercially available pen devices (HUMIRA® Pen) generally include a pre-filled 1 ml glass syringe pre-filled with 0.8 ml of a sterile formulation of 40 mg Adalimumab (see below) with a solid needle (either gray natural gum or a latex-free version) and a needle protector. Commercial Formulations (HUMIRA®) by Adalimumab contain the following ingredients:
Component Quantity per container (mg);(fill volume = 0.8 ml) Amount (mg / ml) adalimumab 40 50 Lemon rem on oh yd rat 1.04 1.3 dibasicnat ri urn phosph atd in hydrate 1.22 1.53 mannitol 9.6 12 monobasicsodium phosph atd in hydrate 0.69 0.86 Polysorbate 80 0.8 1 Sodium chloride 4.93 6.16
DK 201800071 Y4
Sodium 0.24 0.3 WFI and sodium hydroxide q.b. to set the pH to 5.2 q.b to set the pH to 5.2
Adalimumab, and its mode of preparation, are described in WO997 / 29131 (BASF) as D2E7, and elsewhere in the professional literature.
Although the aforementioned commercial formulation of Adalimumab is stable (at least to some extent), the relevant antibody may be unstable over extended periods of time or under stressed conditions, precluding longer storage of the formulations. Such degradation of the formulation may be due to several factors including:
Physical effects, such as:
o Inadequate aggregation inhibition of the relevant protein molecules (a function to be performed by Tween-80);
o Inadequate precipitation inhibition;
o Inadequate adsorption inhibition of the relevant protein molecules in the water-air interface or at the contact surface of any packaging material (a function to be performed by Tween-80);
o Inadequate control of osmotic pressure (a function to be performed by mannitol);
Chemical effects, such as:
o Insufficient oxidation regulation (a function to be performed by mannitol and potentially undermined by Tween-80 which can promote the oxidation of double bonds);
o Insufficient photooxidation inhibition;
o Inadequate inhibition of the hydrolysis of ester bonds leading to the formation of acid, aldehyde and peroxide products, thereby affecting the stability of the antibody;
o Inadequate stabilization and maintenance of the pH;
o Inadequate inhibition of protein fragmentation;
o Inadequate inhibition of protein unfolding.
Any, any or all of the above factors can lead to either an unsustainable drug product (which may be unsafe for use in medical treatments) or a drug product whose viability is variable and unpredictable, especially in light of various stresses (movement, heat, light) to which various portions of the drug product may be subjected
DK 201800071 Y4 manufacture, transport and storage.
With regard to the physical and chemical stabilization of Adalimumab, the complex range of constituents in the aforementioned commercial formulations appears to be performing poorer than expected, especially in view of the large number of constituents. Although this particular combination of excipients undoubtedly represents a '' delicate balance '' (given the interplay of various technical factors) and was the result of extensive research and development work, it is doubtful whether such a combination of research and development will allow such a a high number of different excipients is warranted, especially given that this inevitably increases the manufacturing and cost burdens, toxicity risks and the risk of harmful interactions between components that can compromise the formulation. Even if the overall function of the commercial formulations could not be surpassed, an alternative formulation with comparable function but containing fewer constituents would represent a highly desirable substitute for the commercial formulations for at least the aforementioned reasons.
To guarantee reproducible clinical function of a protein-based pharmaceutical product, it must remain in a stable and consistent form over time. It is well known that molecular changes can occur at all stages of the manufacturing process, including during the final formulation production and during storage. Molecular changes can alter a quality property of a biopharmaceutical product, resulting in an undesirable change in the identity, strength or purity of the product. Some such issues are outlined above.
The primary aim of the formulation development is to provide a pharmaceutical composition which will support the stability of a biopharmaceutical protein at all stages of its production, storage, transport and use. Formulation development of an innovative biopharmaceutical protein or a biosimilar monoclonal antibody (mAb) is critical to its safety, clinical efficacy and commercial success.
Therefore, there is a need to provide alternative or improved liquid formulations of adalimumab. Preferably, new formulations should solve at least one of the aforementioned problems and / or at least one problem inherent in the prior art, and could suitably solve two or more of these problems. It is desirable whether the problem or problems in the prior art could be solved while reducing the complexity of the formulation.
Summary of the production
According to a first aspect of the manufacture, a liquid is provided
Pharmaceutical composition according to the claims The composition optionally comprises (or excludes) one or more additional ingredients defined herein in connection with a liquid pharmaceutical composition (e.g., including tonic, without arginine, etc.), optionally in any amount , concentration or form set forth herein; and wherein the composition optionally exhibits one or more parameters or properties mentioned herein in connection with a liquid pharmaceutical composition (e.g., pH, osmolality, accumulation / aggregation, fragmentation, protein unfolding, turbidity, etc.).
According to one aspect of the preparation, there is provided a drug dispensing device (e.g., a pre-filled syringe or pen or intravenous bag) comprising a liquid pharmaceutical composition as defined herein.
The preparation is provided by a process for preparing a liquid pharmaceutical composition which comprises admixing adalimumab; a histidine buffering agent (or histidine buffer system); a sugar stabilizer; and optionally one or more additional components defined herein in connection with a liquid pharmaceutical composition, optionally in any amount, concentration or form determined; and optionally setting one or more parameters given here in connection with a liquid pharmaceutical composition (e.g., pH, osmolality).
The preparation is provided in a liquid pharmaceutical composition which is obtainable, obtained or obtained directly by a process for preparing a liquid pharmaceutical composition as defined herein.
The preparation is provided by a method of preparing a package or a drug dispensing device which comprises incorporating a liquid pharmaceutical composition as defined herein into a package or drug dispensing device.
The manufacture is provided in a package or drug dispensing device which is obtainable, is obtained or obtained directly by a process for the preparation of a package or drug dispensing device as defined herein.
According to a further aspect of the preparation, a liquid pharmaceutical composition as defined herein is provided for use in the treatment of rheumatoid arthritis, psoriatic arthritis, Bechterew's disease, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and / or rheumatoid arthritis.
Any feature, including optional, suitable and preferred features described in connection with a given aspect of the production, may also be features, including 201800071 Y4, which are optional, suitable and preferred features of any other aspect of the production.
Brief description of the drawings
For a better understanding of the invention, and to show how embodiments thereof are implemented, reference is now made by way of example to the following diagrammatic drawings, in which:
Figure 1 is a bar graph showing the protein content (mg / ml), as determined by OD, of DoE1 formulations (from Example 1) along with standard references (representing HUMIRA® comparison formulations) at an arbitrary starting point (blue bars, time = 0 ) and after 4 weeks (red bars) for formulations heated to 40 ° C.
Figure 2 is a bar graph showing% accumulation, as determined by SEHPLC, of the DoE1 formulations (from Example 1) along with standard references (representing HUMIRA® comparison formulations) at an arbitrary starting point (blue bars, time = 0) and after both 2 weeks (green bars) and 4 weeks (orange bars) for formulations heated to 40 ° C.
Figure 3 is a bar graph showing% fragmentation, as determined with a Bioanalyzer, of the DoE1 formulations (from Example 1) along with standard references (representing HUMIRA® comparison formulations) at an arbitrary starting point (dark blue bars, time = 0) and after both 2 weeks (pink bars) and 4 weeks (light blue bars) for formulations heated to 40 ° C.
Figure 4 is a bar graph showing the unfolding temperature (° C), as determined by DSF, for the DoE1 formulations (from Example 1) along with standard references (representing HUMIRA® comparison formulations).
Figure 5 is a bar graph showing% aggregation, as determined by SEHPLC, of the DoE2 formulations (from Example 2) together with standard references (representing HUMIRA® comparison formulations) at an arbitrary starting point (red bars, time = 0) and after both 2 weeks (green bars) and 4 weeks (purple bars) for formulations heated to 40 ° C.
Figure 6 is a bar graph showing% fragmentation, as determined with a Bioanalyzer, of the DoE2 formulations (from Example 2) along with standard references (representing HUMIRA® comparison formulations) at an arbitrary starting point (blue bars, time = 0) and after both 2 weeks (red bars) and 4 weeks (green bars) for formulations heated to 40 ° C.
Figure 7 is a bar graph showing the main top isoform profile, as determined by iCE280 analysis, of the DoE2 formulations (from Example 2) at an arDK 201800071 Y4 bitter starting point (blue bars, time = 0) and after both 2 weeks (red bars) and 4 weeks (green bars) for formulations heated to 40 ° C.
Figure 8 is a bar graph showing the cluster cluster topoform profile, as determined by iCE280 analysis, of the DoE2 formulations (from Example 2) at an arbitrary starting point (blue bars, time = 0) and after both 2 weeks (red bars) and 4 weeks (green bars) for formulations heated to 40 ° C.
Figure 9 is a bar graph showing the turbidity, as determined by nephelometry, of the DoE2 formulations (from Example 2) at an arbitrary starting point (blue bars, time = 0) and after both 2 weeks (red bars) and 4 weeks (green columns) for formulations heated to 40 ° C.
Figure 10 is a bar graph showing% accumulation, as determined by SEHPLC, of the DoE2 formulations (from Example 2) at an arbitrary starting point (blue bars, time = 0) and after both 24 hours (red bars) and 48 hours ( green bars) for mechanically moving formulations (shaking).
Figure 11 is a bar graph showing% fragmentation, as determined with a Bioanalyzer, of the DoE2 formulations (from Example 2) at an arbitrary starting point (blue bars, time = 0) and after both 24 hours (red bars) and 48 hours (green bars) for mechanically moving formulations (shaking).
Figure 12 is a bar graph showing% turbidity, as determined by nephelometry, of the DoE2 formulations (from Example 2) at an arbitrary starting point (blue bars, time = 0) and after both 24 hours (red bars) and 48 hours ( green bars) for mechanically moving formulations (shaking).
Figure 13 is a bar graph showing% accumulation, as determined by SEHPLC, of the DoE2 formulations (from Example 2) together with standard references (representing HUMIRA® comparison formulations) before exposure to light (blue bars, time = 0) and after 7 hours of light exposure at 765 W / m ² (red bars).
Figure 14 is a bar graph showing% fragmentation, as determined with a Bioanalyzer, of the DoE2 formulations (from Example 2) before exposure to light (blue bars, time = 0) and after 7 hours of light exposure at 765 W / m ² ( red bars).
Figure 15 is a bar graph showing the main top isoform profile, as determined by iCE280 analysis, of the DoE2 formulations (from Example 2) together with standard references (representing HUMI RA® comparison formulations) before exposure to light (blue bars, time = 0) and after 7 hours of light exposure at 765 W / m ² (red bars).
Figure 16 is a bar chart showing the cluster cluster topoform profile which
DK 201800071 Y4 determined by iCE280 analysis, of DoE2 formulations (from Example 2) together with standard references (representing HUMI RA® comparison formulations) before exposure to light (blue bars, time = 0) and after 7 hours of light exposure at 765 W / m ² (red bars).
Figure 17 is a bar graph showing the turbidity, as determined by nephelometry, of the DoE2 formulations (from Example 2) before exposure to light (blue bars, time = 0) and after 7 hours of light exposure at 765 W / m ² (red bars) ).
Figure 18 is a bar graph showing the main top isoform profile, as determined by iCE280 analysis, of the DoE2 formulations (from Example 2) before (blue bars, time = 0) and after (red bars) five freeze-thaw cycles (-80 ° C -> room temperature).
Figure 19 is a bar graph showing the cluster cluster topoform profile, as determined by iCE280 analysis, of the DoE2 formulations (from Example 2) before (blue bars, time = 0) and after (red bars) five freeze thaw cycles (-80 ° C -> room temperature).
Figure 20 is a bar graph showing% accumulation, as determined by SEHPLC, of the DoE2 formulations (from Example 2) along with standard references (representing HUMIRA® comparison formulations) before (blue bars, time = 0) and after (red bars) five freeze-thaw cycles (-80 ° C -> room temperature).
Figure 21 is a bar graph showing the number concentration (# / mg) of invisible particles having a particle size below or equal to 10 micrometers, as determined by count analysis of invisible particles, of the DoE2 formulations (from Example 2) before (blue bars) , time = 0) and after (red bars) five freeze-thaw cycles (-80 ° C -> room temperature).
Figure 22 is a bar graph showing the number concentration (# / mg) of invisible particles having a particle size below or equal to 25 micrometers, as determined by count analysis of invisible particles, of the DoE2 formulations (from Example 2) before (blue bars) , time = 0) and after (red bars) five freeze-thaw cycles (-80 ° C -> room temperature).
Detailed description of the production
definitions
Unless otherwise stated, the following terms used in the specification and claims have the following meanings given below.
References herein to '' adalimumab '' include the original drug substance (as commercially available) adalimumab as defined in
DK 201800071 Y4
WO97 / 29131 (BASF) (in particular D2E7 therein) and elsewhere in the technical field, and also biosimilar agents thereof. D2E7k in WO97 / 29131 "has a CDR3 light chain domain comprising the amino acid sequence of SEQ ID NO: 3 and a CDR3 heavy chain domain comprising the amino acid sequence of SEQ ID NO: 4". Preferably, the D2E7 antibody has a variable light chain region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a variable heavy chain region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2. WO97 / 29131 provides details for each of these sequence entries. References herein to "adalimumab" may include biosimilar agents which may have, for example, at least 75%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 96%, preferably at least 97%. , preferably at least 98% or most preferably at least 99% protein sequence similarity with any of the protein sequences described in either WO97 / 29131 (especially with respect to D2E7) or elsewhere with respect to '' adalimumab ''. Alternatively or additionally, references herein to "adalimumab" may include biosimilar agents which exhibit at least 75%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 96%, preferably at least 97%. , preferably at least 98% or most preferably at least 99% protein sequence homology with any of the protein sequences described in either WO97 / 29131 (especially with respect to D2E7) or elsewhere with respect to '' adalimumab ''. Alternatively or additionally, a biosimilar agent may have a (slightly) different glycosylation profile, although the protein sequence is essentially the same or different to the extent indicated above.
The term "biosimilar agent" (also known as "follow-on biologies") is well known in the art, and those of skill in the art will know immediately when a drug substance can be considered a biosimilar agent for adalimumab. In addition, such "biosimilar agents" would have to be officially approved as a biosimilar agent for marketing before the biosimilar agent is placed on the market. The term "biosimilary agent" is generally used to describe subsequent versions (usually from another source) of a biopharmaceutical original product (biotechnological product whose drug substance is formed from a living organism or is derived from a living organism or through recombinant DNA or guided gene expression methodology ), which was previously granted marketing authorization. Since biotechnological products have a high degree of molecular complexity and are generally vulnerable to changes in the manufacturing processes (eg if different cell lines are used in their production), and
Since subsequent follow-on manufacturers do not normally have access to the original product's molecular clone, cell bank, know-how with regard to fermentation and purification processes, or to the active drug substance itself (only the original manufacturer's drug product in the market), it is unlikely that a given ' 'biosimilar agent' is exactly the same as the original preparation.
For the purpose of various molar calculations (e.g. molar ratio of adalimumab to another component of the liquid pharmaceutical composition of the invention), the molecular weight of adalimumab can be estimated at 144190.3 g / mol (reference molecular weight) based on details given in the CAS database for CAS # 331731-18-1, Adalimumab, wherein the molecular formula is given as C6428H9912N1694O1987S46. As such, a liquid pharmaceutical composition containing 50 mg / ml adalimumab can be considered a 0.347 mM (or 347 μΜ) solution of adalimumab. This is not intended in any way limiting as to the nature of a given biosimilar agent, covered by the scope of protection of the present invention or as to the level of glycosylation, each of which may affect the molecular weight. However, where a biosimilar agent has a different molecular weight, the above reference molecular weight should be used to assess whether such biosimilar agent falls within the scope of molar definitions set forth in this specification. So the molar number in a known weight amount of the biosimilar agent should be calculated for the purpose of this production using the above reference molecular weight.
The term "buffer" or "buffer solution" refers to a generally aqueous solution comprising a mixture of an acid (usually a weak acid, e.g., acetic acid, citric acid, imidazolium form of histidine) and its corresponding base (e.g. an acetate or citrate salt, for example, sodium acetate, sodium citrate or histidine) or, alternatively, a mixture of a base (usually a weak base, e.g., histidine) and its corresponding acid (e.g., protonated histidine salt). The pH of a buffer solution will change only slightly with the addition of a small amount of strong acid or base due to the buffering effect imparted by the buffering agent.
A "buffer system" herein includes one or more buffering agents and / or a corresponding acid / base thereto, and suitably comprises only one buffering agent and a corresponding acid / base thereto. Unless otherwise stated, concentrations determined herein in connection with a buffer system (ie, a buffer concentration) refer to the total concentration of all the relevant buffer elements (i.e., the elements in association with each other, eg citrate / citric acid). As seen in a given concentration of a histidine buffer system in general, the total concentration of histidine and the imidazolium form of histidine are generally related. However, with respect to histidine, such concentrations can usually be calculated without further consideration on the basis of the amount of histidine added or a salt thereof. The overall pH of the composition comprising the relevant buffer system is generally a reflection of the equilibrium concentration of each of the relevant buffer elements (i.e., the balance between buffer agents and corresponding acids and bases thereof).
The term "buffer" herein refers to an acid or base component (usually a weak acid or base) in a buffer or buffer solution. A buffering agent helps maintain the pH of a given solution at or near a predetermined value and the buffering agents are generally selected to complement the predetermined value. Suitably, a buffering agent is a single compound which gives rise to a desired buffering effect, especially when the buffering agent is mixed with (and preferably capable of proton exchange with) an appropriate amount (depending on the desired predetermined pH) of its corresponding acid / base , or if the required amount of its corresponding acid / base is formed in situ - this can be achieved by adding strong acid or base until the desired pH is reached. As an example:
• A histidine buffer is the free amino acid, histidine. Since amino acids such as histidine are amphoteric and thus capable of acting as both an acid and a base, the buffering agent is simply the amphoteric compound itself (preferably in zwitterionic form). However, a histidine buffer system or buffer solution may optionally have added in addition to histidine an amount of acid (preferably a strong acid such as hydrochloric acid) or base (preferably a strong base such as sodium hydroxide) until the desired pH value is reached. As such, some of the histidine present may exhibit a different state of protonation than the zwitterionic amino acid. In this context, unless otherwise indicated, all concentrations given in connection with a histidine buffer system preferably refer to the combined concentration of buffer agent (e.g., histidine) and / or corresponding acids / bases thereof (e.g., the imidazolium form of histidine). Those skilled in the art can readily calculate such concentrations, and can do so by simply referring to the amounts of histidine or its corresponding acid / base. (eg histidine hydrochloride). Such concentrations can be calculated by reference to the combined concentrations
GB 201800071 Y4s of buffer agents and corresponding acid / base, where a buffer system forms by simply mixing buffer agents and corresponding acid / base. Alternatively, such concentrations may conveniently be calculated by reference to the starting amounts / concentrations of the buffering agents or corresponding acids / bases, respectively, wherein a buffer system is formed by mixing either the buffering agents or the corresponding acids / bases with a pH of 11 µm. idd electricity (e.g. strong acid or strong base) to form a mixture of each. Where e.g. a buffer system is formed using a known amount / concentration of histidine, which is mixed with a pH of 11 µg (eg sodium hydroxide) until the desired pH value is reached, the concentration of the buffer system can be calculated with reference to the original amount of histidine. Likewise, the same applies where a buffer system is formed using a known amount / concentration of histidine imidazolium salt (e.g., histidine hydrochloride) mixed with a pH of 11 µm (e.g. sodium hydroxide) until desired pH value is reached - in this case, the concentration of the buffer system can be calculated by reference to the original amount of histidine imidazolium salt.
Herein, a '' corresponding acid / base '' refers to the corresponding acid or base (whichever is relevant at a given pH value - typically the corresponding acid in the context of the present invention) to a given buffering agent. The corresponding acid / base of a histidine buffer agent (e.g., histidine) is preferably the imidazolium form of histidine, preferably an imidazolium salt of histidine. The imidazolium form of histidine can be referred to herein as '' imidazolium-histidine '' and has the following structure:
h ₃ iT — ch — c — o
An imidazolium salt of histidine may be referred to as a histidinimidazolium salt and substantially the same structure as shown above, except for an associated counterion.
The term '' buffer element '' refers to special element (exclusive
DK 201800071 Y4 any associated counter anions or counter cations - ie disregard chloride or hydroxy counterions for histidine / imidazolium-histidine systems) in a given buffer system that is in dynamic equilibrium with (and proton exchange with) one another. For example, histidine and imidazolium-histidine may together constitute the histidine buffer element of a histidine buffer system.
Since it can often be somewhat difficult to define amounts (whether absolute or relative) of a buffer system by reference to the weight (since the total weight will depend on the desired pH which will affect the amount of counterions present), weight-based amounts can herein is instead determined by reference to a theoretical weight of the relevant buffer element. At least two elements are usually present in a given amount of buffer elements (relative amounts which can only be determined by reference to the pH), each with a different molecular weight (which usually differs by only 1). Therefore, for this purpose, the weight of a given set of buffer elements is given as a theoretical weight based on only one of the buffer elements, namely the most basic of the buffer elements (i.e., the least protonated form at a given pH) to enable durable weight calculations. - and referrals. So, the weight of a given amount of buffer elements is given as the weight of base element equivalents. By way of example, the histidine buffer element of a histidine buffer system may consist of histidine and imidazolium-histidine cations. Therefore, the weight of the buffer element is calculated as if histidine was the only element present in the buffer system (although imidazolium-histidine is present with histidine). Thus, any reference to a weight or weight ratio of a histidine buffer element preferably refers to the theoretical weight of histidine equivalents in the buffer system. As such, the initial weight of histidine, in which a composition is formed by adding a pH adjusting agent (e.g., sodium hydroxide) to a fixed amount of imidazolium histidine or even to a fixed amount of histidine (which preferably forms an amount of imidazolium histidine upon dissolution) in the diluent) is considered to be the weight of the buffer element regardless of the final pH value. Alternatively, if the concentration (i.e., the molarity) of a buffer system is known, it can be converted to a weight of buffer element by reference to the molecular weight of the most basic form of the relevant buffer element (e.g., histidine) and by ignoring the fact that imidazolium -histidine cations are also present.
DK 201800071 Y4
Unless otherwise stated, references herein refer to an '' amino acid '' or '' amino acids '', either specific (e.g., arginine, histidine) or general (e.g., any amino acid), in the context of their presence or in compositions. (in particular pharmaceutical liquid compositions of the invention) for the corresponding free amino acids (regardless of their protonation state and / or salt form, but for the sake of uniformity, amounts are preferably calculated with reference to the free amino acid per se). This may suitably include natural and / or artificial amino acids. Unless otherwise indicated, such references are not intended to relate to amino acid residues covalently incorporated as part of a larger compound (as opposed to a composition comprising multiple compounds), such as a peptide or protein (where such amino acid residues are linked via peptide bonds) . Although adalimumab as a protein contains amino acid residues, it is not considered as such to include some free amino acids. By way of example, a composition defined as being free of arginine does not contain free arginine, but it may still contain one or more proteins (e.g., adalimumab) which itself contains arginine residues.
Unless otherwise stated, references herein refer to one or more amino acids, either specific or general, preferably to the L stereoisomers or a racemate thereof, preferably L-amino acids.
The term "substantially free of" when used in conjunction with a given constituent of a composition (e.g., a liquid pharmaceutical composition substantially free of arginine) refers to a composition for which substantially none of the said component has been added. As explained above, such references do not relate to the presence of amino acid residues in a protein structure. When a composition is "substantially free" of a given component, the composition preferably comprises no more than 0.01% by weight of the component, preferably no more than 0.001% by weight of the component, preferably no more than 0.0001% by weight. weight of the component, preferably not more than 0.00001% by weight of the component, preferably not more than 0.000001% by weight of the component, preferably not more than 0.000000001% by weight of the component, most preferably not more than 0, 0001 ppb (by weight).
The term '' completely free of '' when used in conjunction with a given constituent of a composition (e.g. a liquid pharmaceutical composition completely free of arginine) refers to a composition containing none of said constituent. As explained above, such references do not relate to the presence of amino acid residues in a protein structure.
In the context of this specification, a "strong acid" is preferably one with a pK _a value of -1.0 or less, while a "weak acid" is preferably one with a pK _a value of 2.0 or more. In the context of this specification, a "strong base" is preferably one whose corresponding acid has a pK _a value of 12 or greater (preferably 14 or greater), while a "weak base" is preferably one whose corresponding acid has a pK _a value of 10 or less.
A '' stabilizer '' refers to an ingredient which facilitates the maintenance of the structural integrity of the biopharmaceutical, especially during freezing and / or freeze-drying and / or storage (especially during exposure to loads). This stabilizing effect can occur for all sorts of reasons, however, such stabilizers can typically act as osmolytes that protect against protein denaturation. Typically, stabilizers include amino acids (i.e., free amino acids that are not part of a peptide or protein - for example, glycine, arginine, histidine, aspartic acid, lysine) and sugar stabilizers such as a sugar polyalcohol (e.g. mannitol, sorbitol) and / or a disaccharide (e.g., trehalose, sucrose, maltose, lactose), although the liquid pharmaceutical compositions of the invention include a stabilizer, at least one of which is a sugar stabilizer (i.e., either a sugar alcohol or a disaccharide). Preferably, the at least one sugar stabilizer is a non-reducing sugar substance (be it a sugar alcohol or a disaccharide).
Here, a "non-reducing sugar" is usually a sugar without aldehyde groups or without the ability to form an aldehyde group (eg by isomerism).
A "tonicity modifier" or a "tonizer" refers to a composition whose inclusion in a composition appropriately contributes to (or enhances) the overall osmolality and osmolarity of the composition. Preferably, a tonizing agent as used herein includes an agent which makes a solution similar to physiological fluids for osmotic characteristics.
References to specific quantities of a given component of a
Y4 composition, in particular a buffering agent, stabilizer, amino acid, surfactant or tonizing agent, preferably refers to the amounts of the pure anhydrous form of the relevant ingredient (or compounds formed using these amounts of the pure anhydrous form), although such an ingredient may be used in a non-anhydrous form when the composition is formed. Amounts of similar non-anhydrous forms (eg, monohydrates, dihydrates, etc.) can be calculated simply by simply using the appropriate multiplier. For example, unless otherwise stated, amounts determined for trehalose (as in the Examples where amounts relate to trehalose dihydrate) refer to the anhydrous form of trehalose (or compositions formed using the determined amounts / concentrations of anhydrous trehalose) which have a molecular weight of 342,296 g / mol, so to calculate the corresponding amount of trehalose dihydrate needed to form the same compound (less water needs to be added), it is necessary to multiply the amount determined by 378,33 / 342,296 since 378.33 is the molecular weight of trehalose dihydrate. The person skilled in the art will readily understand by adjusting the amount of diluent / water, depending on the shape of the ingredients used, to deduce the target concentrations.
The term "pharmaceutical composition" here refers to a formulation of a pharmaceutical active ingredient which makes the biological activity of the active ingredient therapeutically effective but does not include other ingredients which are obviously toxic to an individual to which the formulation is intended to be administered.
The term "stable" herein refers generally to the physical stability and / or chemical stability and / or biological stability of a component, typically an active substance or composition thereof during preservation / storage.
It should be understood that references to "treating" or "treating" include prevention as well as alleviating established symptoms of a condition. Therefore, treating or treating a condition, disorder or disorder includes: (1) preventing or delaying the appearance of clinical symptoms of the condition, disorder or disorder that develops in a person who may be afflicted or predisposed to the condition, the disorder; or the disorder, but not yet experiencing or exhibiting clinical or subclinical symptoms of the condition, disorder or disorder; (2) inhibiting the condition, disorder or disorder; stop, reduce or
Delay the progression or recurrence of the disease (in the case of maintenance therapy) or at least one clinical or subclinical symptom thereof, or (3) to alleviate or attenuate the disease, ie. cause regression of the condition, disorder or disorder, or at least one of its clinical or subclinical symptoms.
For purposes of this invention, "a therapeutically effective amount" or "effective amount" of the antibody means an amount effective when administered to a mammal to treat a disease or disorder in a prophylactic and therapeutic sense, and the antibody is effective to treatment of the diseases in question.
The therapeutically effective amount will vary depending on the compound, the disease and its severity as well as the age, weight, etc. of the mammal to be treated.
The term "human TNF-α" refers to the human cytokine which exists in a secreted 17 kD form and a membrane associated 26 kD form, and in a biologically active form, TNF-α is seen as a trimer of a covalently bound 17 kD molecule. Its specific structure can be found in Pennica, D. et al. (1984) Nature 312: 724-729; Davis, J.M. et al. (1987) Biochemistry 26, 1322-1326; and Jones, E.Y et al. (1989) Nature 338: 225-228.
The term '' recombinant human antibody '' shall include a human antibody produced, expressed, produced or isolated using a recombinant method.
Quantities provided herein for constituents and ingredients, whether specified in '' parts '', ppm (parts per million) percentages (%, eg% by weight) or ratios are by weight unless otherwise specified indicated.
When the amount or concentration of a given component of a given composition is given as a percentage by weight (% by weight or% v / v), the percentage by weight refers to the percentage of the component by weight relative to the total weight of the composition as a whole. Those skilled in the art will appreciate that the sum of percentages by weight of all components of a composition (specified or not) will amount to a total of 100% by weight. However, where not all ingredients are enumerated (e.g., where compositions are said to comprise one or more particular ingredients), the weight percent balance may optionally be supplemented to 100% by weight of unspecified ingredients (e.g., a diluent such as water or other non - essential but suitable forDK 201800071 Y4 phrases).
Here, the term "parts" (e.g., parts by weight, pbw) when used in conjunction with multiple ingredients / ingredients refers to relative proportions between the multiple ingredients / ingredients. Expressing molar or weight ratios of two, three or more constituents gives rise to the same effect (e.g., a molar ratio of x, y and z xi: yr zi, respectively, or an interval xi-X2: yi-y2 : Z1-Z2). Although the amounts of individual ingredients in a composition in many embodiments can be given as a weight percent value, some or all such weight percent values in alternative embodiments may be converted to parts by weight (or relative ratio) to define a composition of multiple ingredients. It is thus because the relative proportions of the constituents are often more important than the absolute concentrations thereof in the liquid pharmaceutical compositions of the invention. Where a composition comprising several constituents is described solely by parts by weight (i.e., to indicate only relative ratios of constituents), it is not necessary to determine the absolute amounts or concentrations of the constituents (either in whole or individually), because the benefit of production may result. from the relative proportions of the respective constituents rather than from their absolute quantities or concentrations. However, in certain constituents, such compositions consist essentially of or consist of the constituents and a diluent (e.g., water).
Where a composition is said to comprise multiple constituents (optionally in fixed amounts or concentrations), the composition may optionally include additional constituents in addition to the constituents. However, in certain embodiments, a composition which is said to comprise several constituent constituents can actually consist essentially or consist of all the constituent components.
Where a composition herein is said to "substantially consist" of a given component, the compound preferably comprises at least 70% by weight of the component, preferably at least 90% thereof, preferably at least 95% thereof, most preferably at least 99% thereof. Preferably, a composition said to consist essentially of a given component consists of that component except one or more trace impurities.
The term "particle size" or "pore size" refers herein
Y4, respectively, to the length of the longest dimension of a given particle or pore. Both sizes can be measured using a laser particle size analyzer and / or electron microscopes (tunnel electron microscope, TEM, or scanning electron microscope, SEM). The particle number (for any given size) can be obtained using the protocols and equipment described in the Examples which relate to counting of invisible particles.
Liquid pharmaceutical composition
The liquid pharmaceutical composition preferably comprises a human monoclonal antibody, preferably one which inhibits human TNF activity, preferably so that activation of TNF receptors is inhibited. Most preferably, the liquid pharmaceutical compositions comprise adalumimab, which itself preferably includes any biosimilar agents therefor. Preferably, compositions comprise a histidine buffer agent (or histidine buffer system). Preferably, the composition comprises a sugar stabilizer. Preferably, the composition has a pH value above or equal to 6.30. The composition is preferably (substantially or completely) free of arginine or comprises arginine either at a concentration of not more than 0.1 mM, in a mole ratio of arginine to histidine buffer agent (or histidine buffer system) of at most 1: 1 50, or in a weight ratio of arginine and adalimumab not exceeding 1: 3000 (ie less than or equal to one part by weight of histidine for each 3000 parts by weight of histidine buffer). Alternatively or additionally, the composition may conveniently include any one or more additional components defined herein in connection with a liquid pharmaceutical composition (i.e., including tonic, exclusive arginine, etc.), optionally in any amount, concentration or form set forth herein. ; and wherein the composition optionally exhibits any one or more parameters or properties given herein in connection with a liquid pharmaceutical composition (e.g., pH, osmolality).
The preparation advantageously provides alternative and improved liquid pharmaceutical compositions which generally exhibit better stability and viability than the prior art. As shown herein (see Examples), the liquid pharmaceutical formulations of the preparation have comparable or improved properties as compared to conventional formulations of adalimumab, e.g.
GB 201800071 Y4 available formulation Humira® when subjected to various stressful conditions (thermal, mechanical and light). Their performance is also generally comparable to or better than many other comparison formulations that underwent the same stress test. Since these stressful conditions are highly representative of the type of stresses to which such formulations are subjected during manufacture, transport and storage, they provide an excellent indication of the benefits of production. That such good stability can be achieved with less complex formulations with fewer excipients was considered surprising given the general teachings of the prior art.
adalimumab
Adalimumab, which is commercially available in HUMIRA® formulations and its method of preparation, is described in WO97 / 29131 (BASF) as D2E7 and elsewhere in the prior art. It is described as having "a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3 and a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4" (wO97 / 29131). In addition, the D2E7 antibody is described as having a variable light chain region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a variable heavy chain region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2 (WO97 / 29131).
Adalimumab's medical indications and function have been described above.
In the context of the invention, "adalimumab" includes biosimilar agents as defined above, and those skilled in the art will readily understand the meaning of the term "adalimumab" in the context of the invention.
In one embodiment, the liquid pharmaceutical composition comprises adalimumab at a concentration of from about 5 to about 150 mg / ml, preferably from about 25 to about 75 mg / ml. For example, adalimumab may be present in the formulation at a concentration of about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, or about 75 mg / ml. In one embodiment, adalimumab is present at a concentration of from about 45 to about 55 mg / ml. In one embodiment, adalimumab is present at a concentration of about 50 mg / ml.
DK 201800071 Y4
Buffer, buffer and pH
The liquid pharmaceutical composition is preferably a buffered solution whose pH is stabilized by a buffer agent (or buffer system), preferably in combination with a corresponding acid / base of the buffer agent. As such, the liquid pharmaceutical composition preferably comprises a buffering agent as defined herein. Preferably, the liquid pharmaceutical composition further comprises a corresponding acid / base, wherein the corresponding acid / base corresponds to the corresponding acid or base of the buffer, depending on whether the buffer itself is a base or an acid, respectively. Taken together, the buffering agent and its corresponding acid / base can be considered a '' buffer system ''. Thus, the liquid pharmaceutical composition preferably comprises a buffer system (preferably comprising one or more buffering agents and one or more corresponding acids / bases), and any concentration determined in connection with the buffer system generally relates to the combined concentrations of buffer agents and corresponding acids / bases. Preferably, any buffer system comprises a weak acid and a weak base (see above definitions).
The buffering agent is preferably a histidine buffering agent. Preferably, the histidine buffer agent is histidine (or a salt thereof), most preferably free histidine (e.g. zwitterionic histidine).
Preferably, the liquid pharmaceutical composition comprises a corresponding acid / base to the buffering agent. This is less straightforward for histidine buffer idles than for many other common carboxylic acid / carboxylate buffer systems, as the imidazole group in histidine causes histidine to generally exist in aqueous solution as an equilibrium mixture of protonated (imidazolium) and deprotonated (free imidazole) forms value between 6 and 7. The protonated (imidazolium) form of histidine may be associated with one or more pharmaceutically acceptable anions - including anions such as hydroxide or chloride - although the imidazolium form exists further or alternatively in a diluent (e.g., water) as a solvate cation. As such, the protonated (imidazolium) form of histidine can be considered as the corresponding acid / base of histidine since it represents the corresponding acid of histidine. Preferably, this corresponding acid to histidine has protonated both the amino and imidazole group, but carboxylate
The DK4 group deprotonated - this gives a positive net charge of + 1. The combination of the buffer and its corresponding acid / base forms a buffer system. Preferably, the liquid pharmaceutical composition comprises the buffering agent and its corresponding acid / base, preferably such that the buffering agent and its corresponding acid / base are present together at a level (i.e. absolute amount or concentration) and in a relative amount (or concentration). sufficient to provide the desired pH value for the composition. The buffer system can be formed by simply mixing the buffering agent (e.g., histidine) with its corresponding acid / base (e.g., imidazolium salt form of histidine, e.g., histidine monohydrochloride), preferably in appropriate amounts to provide a composition of the desired pH -value. Alternatively, the buffer system may be formed by mixing an acid or base with either the buffering agent or its corresponding acid / base to form in situ the desired mixture of buffer agent and corresponding acid / base. For example, the buffer system can be formed by adding a base (e.g., sodium hydroxide) to the buffer (e.g., histidine, which can self-balance immediately when dissolved in water, resulting in both histidine and its corresponding acid) , preferably in an amount appropriate to provide the desired pH and mixture of the buffering agent (e.g., histidine) and the corresponding acid / base (i.e., the imidazolium salt form of histidine). Alternatively, any of the methods for forming the buffer system can be used and the pH value can be adjusted by reasonable assessment either by adding additional acid (preferably strong acid such as HCl) or additional base (preferably strong base such as sodium hydroxide) until the required pH is reached. value is reached.
As described above, a "pH adjusting agent" may be used in conjunction with histidine (or an imidazolium histidine salt, e.g., histidine hydrochloride) to obtain a desired pH value. The H-adjusting agent may be a strong acid or a strong base, although it is preferably a strong base such as sodium hydroxide.
Most preferably, the buffer system is a histidine buffer system, preferably comprising histidine in equilibrium with its imidazolium form.
Preferably, the liquid pharmaceutical composition comprises at most one buffering agent. Preferably, the liquid pharmaceutical composition comprises at most one buffer system.
DK 201800071 Y4
The liquid pharmaceutical composition has a pH greater than or equal to 5.0. Preferably, the liquid pharmaceutical composition has a pH greater than or equal to 6.3. Preferably, the liquid pharmaceutical composition has a pH less than or equal to 6.7.
In a particular embodiment, especially where the buffering agent is a histidine buffering agent, the liquid pharmaceutical composition has a pH between 6.0 and 6.6. In a particular embodiment, the liquid pharmaceutical composition has a pH between 6.3 and 6.5. In a particular embodiment, the liquid pharmaceutical composition has a pH of about 6.4.
The liquid pharmaceutical composition preferably comprises a buffer system (preferably a histidine buffer system comprising a histidine buffer agent) at a concentration of from about 2 to about 50 mM. In one embodiment, the buffer system (s) are present at a concentration of 10 mM. In one embodiment, the liquid pharmaceutical composition comprises histidine (and / or a salt thereof) at a concentration of 10 mM. This suitably includes where the buffering agent (e.g., histidine) is formed by the addition of a strong base (e.g., sodium hydroxide) to the corresponding acid to the buffer (e.g., the imidazolium form of histidine).
The liquid pharmaceutical composition preferably comprises the buffer element (preferably the histidine buffer element - eg histidine itself) at a concentration of from about 0.31 g / ml to about 7.8 mg / ml. In one embodiment, the buffer element is present at a concentration of between 0.77 mg / ml and 2.2 mg / ml, preferably about 1.55 mg / ml. In one embodiment, the buffer system / buffer is present at a concentration of 1.55 mg / ml. This includes where the buffer (e.g., histidine) is formed by the addition of a strong base (e.g., sodium hydroxide) to the corresponding acid to the buffer (e.g., the imidazolium form of histidine).
The liquid pharmaceutical composition preferably comprises the buffer system (preferably the histidine buffer system) in a buffer system-adalimumab molar ratio of from about 5: 1 to about 145: 1. In one embodiment, the buffer system is present in a buffer system to adalimumab molar ratio of from about 14: 1 to about 40: 1, most preferably about 29: 1. In one embodiment, the buffer system (s) are present in a concentration.
DK 201800071 Y4 at 29: 1. This includes where the buffering agents (e.g., histidine) are formed by the addition of a strong base (e.g., sodium hydroxide) to the corresponding acid for the buffering agent (e.g., the imidazolium form of histidine - e.g., histidine monohydrochloride).
As illustrated in the example section, liquid pharmaceutical compositions according to the invention, including a histidine buffer agent / buffer system, perform particularly well in strain tests, especially in terms of fragmentation and protein unfolding, which may be important indicators of stability and drug product durability. In addition, liquid pharmaceutical compositions whose histidine buffer system maintains a stable pH of 6.4 perform particularly well.
sugar stabilizer
The liquid pharmaceutical composition preferably comprises a stabilizer, most preferably a sugar stabilizer. Such a component preferably facilitates the maintenance of the structural integrity of the biopharmaceutical drug, especially during freezing and / or freeze-drying and / or storage (particularly during stress exposure).
The liquid pharmaceutical composition may comprise one or more sugar stabilizers, although only a single sugar stabilizer is present in preferred embodiments.
Preferably, the sugar stabilizer is a sugar poly alcohol (including sugar alcohols) and / or a disaccharide.
The sugar stabilizer is preferably selected from the group including trehalose, mannitol, sucrose, sorbitol, maltose, lactose, xylitol, arabitol, erythritol, lactitol, maltitol, inositol.
In a particular embodiment, the sugar stabilizer is selected from the group including trehalose, mannitol, sucrose, maltose, lactose, xylitol, arabitol, erythritol, lactitol, maltitol, inositol.
In a particular embodiment, the sugar stabilizer is a non-reducing sugar, optionally a non-reducing sugar, listed anywhere herein.
In a particular embodiment, the sugar stabilizer is trehalose. Trehalose is a particularly advantageous sugar stabilizer for use with a histidine buffer agent / buffer system in liquid adalimumab formulations.
DK 201800071 Y4
The liquid pharmaceutical formulation preferably comprises at most one sugar stabilizer, preferably at most one sugar polyol and / or disaccharide. Preferably, the liquid pharmaceutical composition comprises trehalose as the sole sugar stabilizer.
Preferably, the trehalose used to form the liquid pharmaceutical composition is trehalose dihydrate, although all amounts determined in association with trehalose are preferably (unless otherwise stated - as in the Examples) pertaining to pure, anhydrous trehalose. Such amounts can be converted to an amount of trehalose dihydrate using an appropriate multiplier. In addition, an amount of trehalose dihydrate for assessing whether a given formulation falls within some of the trehalose amount definitions given herein can be readily converted to a corresponding amount of pure, anhydrous trehalose (with a corresponding mole number) by using the multiplier inversely. This principle can be used for any sugar stabilizer component. Concentrations, when given as a molar concentration, will, of course, be the same regardless of the hydration state of the sugar stabilizer.
Preferably, the liquid pharmaceutical composition comprises the sugar stabilizer (most preferably trehalose) at a concentration of from 50 to about 400 mM, more preferably from about 100 to about 300 mM, more preferably from about 150 to about 250 mM. In one embodiment, the sugar stabilizer is present at a concentration of between 190 and 210 mM, most preferably about 200 mM. In one embodiment, trehalose is present at a concentration of 200 m Μ.
The liquid pharmaceutical composition preferably comprises the sugar stabilizer (most preferably trehalose) at a concentration of from about 15 mg / ml to about 140 mg / ml, more preferably from about w5 mg / ml to about 100 mg / ml, more preferably from about 45 mg. / l to 80 mg / l. In one embodiment, the sugar stabilizer is present at a concentration of between 65 mg / l and 72 mg / l, most preferably about 68 mg / ml. In a particular embodiment, trehalose is present at a concentration of about 68 mg / ml (which is equivalent to about 75.7 mg / ml trehalose dihydrate).
The liquid pharmaceutical composition preferably comprises the sugar stabilizer (most preferably trehalose) in a sugar stabilizer to adalimumab molar ratio of from about 145: 1 to about 1150: 1, more
Preferably from about 290: 1 to about 860: 1, more preferably from about 430: 1 to about 720: 1. In one embodiment, the sugar stabilizer is present in a molar ratio of sugar stabilizer to adalimumab of from about 550: 1 to about 605: 1, most preferably about 576: 1. In one embodiment, trehalose is present in a mole ratio of trehalose to adalimumab of approximately 576: 1.
As shown in the example section, liquid pharmaceutical compositions according to the invention, including a sugar stabilizer as defined herein, perform particularly well in strain tests, particularly with respect to accumulation, fragmentation and protein unfolding, which may be important indications of stability and drug product durability. In addition, liquid pharmaceutical compositions comprising trehalose as a sugar stabilizer perform particularly well.
Diluent
The liquid pharmaceutical compositions may include any or more pharmaceutically acceptable diluents or a mixture thereof. Most preferably, the liquid pharmaceutical composition is an aqueous pharmaceutical composition. Most preferably, the diluent is water and preferably water alone. The water is preferably water for injection (WFI).
The diluent may comprise the rest of the constituents of a given liquid pharmaceutical composition, for example, so that the total weight percentages are 100%. Preferably, any concentration given herein in relation to any component of the liquid pharmaceutical composition represents the concentration of the component in (and preferably dissolved in) the diluent in admixture with any other component.
The liquid pharmaceutical composition is preferably a solution and is preferably (substantially or completely) free of particles or precipitates.
Absent or sparsely present constituents
Little / no arginine.
The liquid pharmaceutical composition is either (substantially or completely) free of arginine (preferably L-arginine) and comprises arginine at a concentration of at most 0.1 mM, more preferably at most 0.01 mM,
DK 201800071 Y4 most preferably not more than 0.001 mM.
The liquid pharmaceutical composition is either (substantially or completely) free of arginine (preferably L-arginine) or comprises arginine in an arginine-to-buffer (or buffer system) molar ratio of not more than 1: 150 (i.e., less than or equal to one). mole of arginine for every 150 moles of buffer or buffer system), more preferably not more than 1: 1500, most preferably 1: 1, 5,000.
The liquid pharmaceutical composition is either (substantially or completely) free of arginine (preferably L-arginine) or comprises arginine in a weight ratio of arginine to adalimumab of not more than 1: 3000 (i.e. less than or equal to some arginine by weight). for every 3000 parts of adalimumab by weight), more preferably not more than 1: 30,000, most preferably not more than 1: 300,000.
The liquid pharmaceutical composition is either (substantially or completely) free of arginine (preferably L-arginine) or comprises arginine in a mole ratio of arginine to adalimumab of not more than 1: 3.75 (i.e., less than or equal to one mole of arginine for each 3.75 moles of adalimumab), more preferably not more than 1: 37.5, most preferably not more than 1: 375.
As explained herein, such references to "arginine" in the context of their presence or not in liquid pharmaceutical compositions relate to the corresponding free amino acids and not amino acid residues covalently incorporated as part of a larger compound such as a peptide or protein.
As shown in the example section, liquid pharmaceutical compositions according to the invention which (substantially or completely) exclude arginine, perform particularly well in stress tests, particularly with regard to accumulation, fragmentation and protein unfolding.
Few / no amino acids.
The liquid pharmaceutical composition is either (substantially or completely) free of amino acids other than histidine (which is preferably the buffering agent) or comprises one or more amino acids other than histidine at a (total) concentration of at most 0.1 mM, more preferably at most 0.01 mM, most preferably 0.001 mM.
The liquid pharmaceutical composition is either (substantially or completely) free of amino acids other than histidine or comprises
One or more non-histidine amino acids in a (total) mole ratio of amino acids to buffer agent (or buffer system) of not more than 1: 150 (i.e., less than or equal to one mole of non-histidine amino acids for each 150 moles of buffer or buffer system), more preferably not more than 1: 1500, most preferably 1: 1 5,000.
The liquid pharmaceutical composition is either (substantially or completely) free of amino acids other than histidine or comprises one or more non-histidine amino acids in a (total) amino acid to adalimumab weight ratio of not more than 1: 3000 (i.e. less than or corresponding to a portion of non-histidine amino acids by weight for each 3000 parts of adalimumab by weight), more preferably not more than 1: 30,000, most preferably no more than 1: 300,000.
The liquid pharmaceutical composition is either (substantially or completely) free of amino acids other than histidine or comprises one or more non-histidine amino acids in a (total) amino acid to adalimumab molar ratio of not more than 1: 3.75 (i.e. less than or equal to one mole of non-histidine amino acids for each 3.75 moles of adalimumab), more preferably at most 1: 37.5, most preferably at most 1: 375.
As explained herein, such references to '' amino acids '' in the context of their presence or not in liquid pharmaceutical compositions relate to the corresponding free amino acids and not amino acid residues covalently incorporated as part of a major compound such as a peptide or protein.
The amino acids referred to in this section (and considered to be either absent or present in small amounts) may conveniently be natural and / or artificial amino acids, although they are preferably natural amino acids. In particular, the liquid pharmaceutical compositions are either (substantially or completely) free of any amino acid selected from the group including: arginine, lysine and aspartic acid; or comprises one or more of the aforementioned amino acids in an amount, concentration, molar ratio or weight ratio as previously defined for non-histidine amino acids.
As shown in the example section, liquid pharmaceutical compositions according to the invention which (substantially or completely) exclude non-histidine amino acids perform well in stress tests.
DK 201800071 Y4 in particular with regard to accumulation, fragmentation and protein unfolding.
Scarce / no surfactants.
The liquid pharmaceutical composition is either (substantially or completely) free of surfactants (be it cationic, anionic, amphoteric or nonionic) with the possible exception of polysorbate 80 (polyoxyethylene (20) sorbitan monoeleate) or comprises one or more of said surfactants (optionally without polysorbate 80) at a (total) concentration of not more than 1 mM, more preferably not more than 0.1 mM, more preferably not more than 0.01 mM, more preferably not more than 0.001 mM, most preferably not more than 0.00001 mM . The liquid pharmaceutical composition may optionally comprise polysorbate 80 as defined herein. However, in preferred embodiments, the liquid pharmaceutical composition is (substantially or completely) free of polysorbate 80 or comprises only polysorbate 80 in the limited amounts / concentrations mentioned above, preferably in common with any other surfactant.
The liquid pharmaceutical composition is either (substantially or completely) free of surfactants (be it cationic, anionic, amphoteric or nonionic) with the possible exception of polysorbate 80 (polyoxyethylene (20) sorbitan monoeleate) or comprises one or more of said surfactants (optionally without polysorbate 80) in a (total) molar ratio of surfactant to buffer (or buffer system) of at most 1:10, more preferably at most 1: 100, more preferably at most 1: 1000, more preferably at most 1: 10,000, most preferably not more than 1: 100,000. The liquid pharmaceutical composition may optionally comprise polysorbate 80 as defined herein. However, in preferred embodiments, the liquid pharmaceutical composition is (substantially or completely) free of polysorbate 80 or comprises only polysorbate 80 in the limited amounts / concentrations mentioned above, preferably in common with any other surfactant.
The liquid pharmaceutical composition is either (substantially or completely) free of surfactants (be it cationic, anionic, amphoteric or nonionic) with the possible exception of
Y 2018 polysorbate 80 (polyoxyethylene (20) sorbitan monoeleate) or comprises one or more of said surfactants (optionally without polysorbate 80) in a (total) weight ratio of surfactant to adalimumab not exceeding 1:50 (i.e. less than or equal to to one part by weight of surfactants for each 50 parts by weight of adalimumab), more preferably not more than 1: 500, more preferably not more than 1: 5000, more preferably not more than 1: 50,000, most preferably not more than 1: 500,000. The liquid pharmaceutical composition may optionally comprise polysorbate 80 as defined herein. However, in preferred embodiments, the liquid pharmaceutical composition is (substantially or completely) free of polysorbate 80 or comprises only polysorbate 80 in the limited amounts / concentrations mentioned above, preferably in common with any other surfactant.
The liquid pharmaceutical composition is either (substantially or completely) free of surfactants (be it cationic, anionic, amphoteric or nonionic) with the possible exception of polysorbate 80 (polyoxyethylene (20) sorbitan monoeleate) or comprises one or more of said surfactants (optionally without polysorbate 80) in a (total) molar ratio of surfactants to adalimumab of not more than 3: 1, more preferably not more than 0.3: 1, more preferably not more than 0.003: 1, more preferably not more than 0.0003: 1, most preferably not more than 0.00003: 1. The liquid pharmaceutical composition may optionally comprise polysorbate 80 as defined herein. However, in preferred embodiments, the liquid pharmaceutical composition is (substantially or completely) free of polysorbate 80 or comprises only polysorbate 80 in the limited amounts / concentrations mentioned above, preferably in common with any other surfactant.
The surfactants referred to in this section (and considered to be either absent or present in small amounts) may preferably be cationic, anionic, amphoteric or nonionic surfactants. Preferably, the surfactants referred to in this section (which are considered either absent or present in small amounts) include cationic, anionic and amphoteric surfactants, but nonionic surfactants may be excluded (e.g., polysorbates). and spans) or may at least possibly be without
As such, the liquid pharmaceutical composition is either (substantially or completely) free of cationic, anionic or amphoteric surfactants or comprises one or more of the surfactants in an amount, concentration, mole ratio or weight ratio not exceeding that set forth in any preceding section of this subchapter with respect to surfactants more generally.
The liquid pharmaceutical composition is either (substantially or completely) free of nonionic surfactants with the exception of polysorbate 80, or comprises one or more of said surfactants in an amount, concentration, mole ratio, or weight ratio not exceeding that of is set out in any of the preceding sections of this subchapter with respect to surfactants more generally.
The liquid pharmaceutical composition is either (substantially or completely) free of surfactants in the form of polysorbate, with the possible exception of polysorbate 80, or comprises one or more of said surfactants in an amount, concentration, mole ratio, or weight ratio not exceeding that, set out in any of the preceding sections of this subchapter with respect to surfactants more generally. In such circumstances, the liquid pharmaceutical composition may optionally comprise polysorbate 80 as defined herein. However, in preferred embodiments, the liquid pharmaceutical composition is (substantially or completely) free of polysorbate 80 or comprises polysorbate 80 in only the limited amounts / concentrations mentioned above, preferably in common with any other surfactants.
The liquid pharmaceutical composition is either (substantially or completely) free of surface active substances in the form of polysorbate 20 (also known as Tween 20 polyoxyethylene (20) sorbitan monolaurate) or comprises one or more of said surfactants in an amount, concentration , molar ratio, or weight ratio not exceeding that set in any of the preceding paragraphs of this subchapter with respect to surfactants more generally.
Preferably, the liquid pharmaceutical composition is either (substantially or completely) free of surfactants in the form of polysorbate 80 or comprises said surfactants in an amount;
Y4 concentration, mole ratio, or weight ratio as defined above with respect to surfactants. The liquid pharmaceutical composition is either (substantially or completely) free of surfactants in the form of polysorbate 80 or comprises one or more of said surfactants in an amount, concentration, mole ratio, or weight ratio not exceeding that set in a any of the preceding sections of this subchapter with respect to surfactants more generally.
As shown in the exemplary portion, liquid pharmaceutical compositions which (substantially or completely) exclude surfactants or certain surfactants as defined above, perform particularly well in stress tests, particularly with respect to accumulation, fragmentation and protein unfolding.
Scarce / no phosphate.
The liquid pharmaceutical composition is preferably either (substantially or completely) free of phosphate buffer agents (e.g., sodium dihydrogen phosphate, disodium hydrogen phosphate) or comprises a phosphate buffer system at a concentration of at most 0.1 mM, more preferably at most 0.01 mM, most preferably not more than 0.001 mM.
Preferably, the liquid pharmaceutical composition is either (substantially or completely) free of phosphate buffer agents (e.g., sodium dihydrogen phosphate, disodium hydrogen phosphate) or comprises a phosphate buffer system in a phosphate buffer system molar ratio of any non-phosphate buffer system present at a maximum of 1: 150 (i.e. less than or equal to one mole of phosphate buffer system for every 150 moles of non-phosphate buffer system present), more preferably not more than 1: 1500, most preferably not more than 1: 15,000.
The liquid pharmaceutical composition is preferably either (substantially or completely) free of phosphate buffer agents or comprises a phosphate buffer system in a phosphate buffer system to adalimumab ratio of not more than 1: 3.75 (i.e. less than or equal to one mole of phosphate buffer system for every 3). 75 moles of adalimumab), more preferably not more than 1: 37.5, most preferably not more than 1: 375.
References to "phosphate buffer agents" in the context of their presence or not in liquid pharmaceutical compositions relate to a
Any phosphate salt in any protonation state including phosphate, monohydrogen phosphate and dihydrogen phosphate. However, any phosphate group or residue which is covalently incorporated as part of a larger compound, such as a phosphorylated or glycosylated peptide or protein, is preferably excluded.
As shown in the exemplary portion, liquid pharmaceutical compositions of the invention which (substantially or completely) exclude phosphate buffer agents are particularly well-versed in stress tests, particularly with respect to accumulation, fragmentation and protein unfolding.
Any additional ingredients
Toning agent.
The liquid pharmaceutical composition preferably comprises a '' tonicity modifier '' (or '' tonic agent '') or one or more tonic agents, preferably as defined herein.
The inclusion of a tonic agent appropriately contributes to (or increases) the overall osmolality and osmolarity of the composition. A tonizing agent is preferably present in the composition in an amount or concentration sufficient for the composition to be (substantially) isotonic with body fluids. A tonizing agent is preferably present in the composition in an amount or concentration sufficient for the composition to have an osmolarity or osmolality at an interval defined herein.
Any suitable tonic may be used. However, the tonic agent is preferably selected from the group including water-soluble metal salts (e.g., sodium chloride, potassium chloride, magnesium chloride, calcium chloride), water-soluble ionizing sugars / sugar alcohols (e.g., glucose, sucrose, mannitol) and / or other water-soluble polyalcohols. The tonic agent is preferably non-buffering (i.e., gives little or no buffering effect). As such, all metal salt tonizers are suitable non-buffering agents.
The liquid pharmaceutical composition may comprise one or more tonic agents, preferably only a single tonic agent is present (notwithstanding any tonic effects imparted to the composition of constituents for a different function as defined herein).
DK 201800071 Y4
Most preferably, the tonizing agent is or comprises a metal salt (preferably a non-buffering water-soluble metal salt). Preferably, the metal salt is or comprises a metal halide, preferably an alkali or alkaline earth metal halide, preferably an alkali metal chloride.
In a particular embodiment, the tonizing agent is or is sodium chloride. In a particular embodiment, the tonic is sodium chloride. Sodium chloride is a particularly advantageous stabilizer for use with a histidine buffer agent / buffer system in liquid adalimumab formulations.
Preferably, the liquid pharmaceutical composition comprises the tonizing agents (most preferably sodium chloride) at a concentration of from about 10 to about 200 mM, more preferably from about 20 to about 100 mM, more preferably from about 25 to about 75 mM. In one embodiment, the tonic agents are present at a concentration of between 40 and 60 mM, most preferably about 50 mM. In one embodiment, sodium chloride is present at a concentration of 50 m Μ.
The liquid pharmaceutical composition preferably comprises the tonizing agents (most preferably sodium chloride) at a concentration of from about 0.5 mg / l to about 12 mg / ml, more preferably from about 1.5 mg / ml to about 4.4 mg / ml. In one embodiment, the tonic agents are present at a concentration of between 2.7 mg / ml and 3.1 mg / ml, most preferably about 2.9 mg / ml. In a particular embodiment, sodium chloride is present at a concentration of about 2.9 mg / ml.
The liquid pharmaceutical composition preferably comprises the tonizing agents (most preferably sodium chloride) in a tonic agent to adalimumab molar ratio of from about 30: 1 to about 580: 1, preferably from about 60: 1 to about 290: 1, more preferably from about 70; 1 to about 220: 1. In one embodiment, the tonic agents are present in a molar ratio of tonic agent to adalimumab of from about 115: 1 to about 175: 1, preferably about 145: 1. In one embodiment, sodium chloride is present in a molar ratio of sodium chloride to adalimumab of approximately 145: 1.
As shown in the exemplary portion, liquid pharmaceutical compositions of the invention which (substantially or completely) exclude phosphate buffer agents are particularly well-versed in stress tests, particularly with respect to accumulation, fragmentation and protein unfolding.
As shown in the example part, liquid pharmaceutical copes
Y4 compositions including a tonizing agent as defined herein are particularly good in stress tests, particularly with respect to accumulation, fragmentation and protein unfolding, which may be important indicators of stability and drug product durability. In addition, pharmaceutical compositions containing sodium chloride, especially in an amount range as indicated, perform particularly well.
Surfactant.
The liquid pharmaceutical composition may comprise a surfactant or surfactant (s), preferably as defined herein.
Any suitable surfactant can be used. However, the surfactant is preferably a nonionic surfactant, most preferably a polysorbate (polyoxyethylene glycol sorbitan alkyl esters) or span (sorbitan alkyl esters) surfactant.
Although one or more surfactants may be included in the liquid pharmaceutical composition, preferably only a single surfactant is present, most preferably a single nonionic surfactant (preferably as defined herein).
The surfactants are preferably selected from
Polysorbate 20 (polyoxyethyl (polyoxyethyl) (polyoxyethylene (polyoxyethylene (20) sorbitan monolaurate), Polysorbate (20) sorbitan monopalmitate), Polysorbate 60 len (20) sorbitan monostearate (Polysorbate len (20) sorbitan monoleate, sorbitan monoleate) or sorbitan monooleate.
In a particular embodiment, the surfactants are selected from Polysorbate 20, Polysorbate 40, Polysorbate 60 and / or Polysorbate 80. In a particular embodiment, the liquid pharmaceutical composition comprises a single surfactant selected from Polysorbate 20, Polysorbate 40, Polysorbate 60 .
In a particular embodiment, the surfactant is polysorbate 80 or polysorbate 20. In a particular embodiment, the surfactant is polysorbate 80.
The liquid pharmaceutical composition preferably comprises the surfactants (most preferably polysorbate 80) at a concentration.
From about 0.0001 to about 5 mM (i.e., 0.1 µΜ-5 mM), more preferably from about 0.001 to about 2 mM, more preferably from about 0.01 to about 1.0 mM. In one embodiment, the surfactant is present at a concentration of between 0.72 and 0.80 mM, most preferably about 0.76 mM. In one embodiment, polysorbate 80 is present at a concentration of 0.76 mM.
Preferably, the liquid pharmaceutical composition comprises the surfactants (most preferably polysorbate 80) at a concentration of from about 0.001 mg / ml to about 5 mg / ml, more preferably from about 0.01 mg / l to about 2 mg / ml, more preferably from about 0.05 mg / ml to about 1.5 mg / ml. In one embodiment, the surfactant is present at a concentration of between 0.9 mg / ml and 1.1 mg / ml, most preferably about 1.0 mg / ml. In one embodiment, polysorbate 80 is present at a concentration of about 1.0 mg / ml.
The liquid pharmaceutical composition preferably comprises the surfactants (most preferably polysorbate 80) in a molar ratio of surfactants to adalimumab of from about 1: 3500 to about 15: 1, more preferably from about 1: 350 to about 6: 1, more preferably from about 1:35 to about 3: 1. In one embodiment, the surfactant is present in a molar ratio of surfactant to adalimumab of from about 2.1: 1 to about 2.3: 1, most preferably about 2.2: 1. In one embodiment, polysorbate 80 is present in molar ratio of polysorbate 80 to adalimumab of about 2.2: 1.
However, in preferred embodiments, the liquid pharmaceutical composition is (substantially or completely) free of polysorbate 80 and preferably (substantially or completely) free of some surfactants at all.
Other parameters of production
Osmolality.
The osmolality of the liquid pharmaceutical composition is preferably between 200 and 400 mOsm / kg, more preferably between 220 and 390 mOsm / kg, more preferably between 230 and 350 mOsm / kg, more preferably between 240 and 340 mOsm / kg, more preferably between 260 and 320 mOsm / kg, most preferably between 280 and 310 mOsm / kg. The relative amounts and concentrations of the various constituent components
The Y4 can be adjusted according to a reasonable assessment to achieve the desired osmolality, and the special new combinations of components allow this to be achieved to a large extent without compromising other important parameters. However, the relative amounts and concentrations of the various constituents of composition may preferably be selected for optimization of other parameters - this disclosure, including the examples and protocols set forth therein, allows the person skilled in the art to accomplish this purpose and realize one, some, or all of the beneficial effects of this invention. .
Proteinudfoldningstemperatur.
The protein unfolding temperature (appropriately measured by the DSF protocols defined herein) for adalimumab in the liquid pharmaceutical composition of the preparation is greater than or equal to 65 ° C, preferably greater than or equal to 70 ° C. The new combination of constituents present in the composition according to the invention allows the person skilled in the art to obtain high unfolding temperatures, which may be considered desirable from a heat stability perspective.
Parameters during exposure to heat stress.
The amount (or concentration) of aggregates (preferably derived from adalimumab and preferably as determined by the SE-HPLC protocols defined herein) present in the liquid pharmaceutical composition preferably increases by at most a factor of 4 (i.e. 4 times the amount relative to an arbitrary starting time) when the composition is heat-loaded to 40 ° C (i.e., the composition is kept at a temperature of 40 ° C) over a period of 28 days, preferably by a factor of at most 3, preferably at most 2.5, preferably at most 2.2.
The amount (or concentration) of fragments (preferably derived from adalimumab and preferably measured by the bioassay protocols defined herein) present in the liquid pharmaceutical composition preferably increases by a maximum of a factor of 4 (i.e., 4 times the amount relative to an arbitrary onset time) when the composition heat-loaded to 40 ° C (i.e., the composition is maintained at a temperature of 40 ° C) over a period of 28 days, preferably by a factor of at most 3, preferably at most 2.5, preferably at most 2.2.
The turbidity (preferably measured by nephelometry in accordance with the protocols set forth herein) of the liquid pharmaceutical composition preferably increases by a maximum of a factor of 2 (i.e. 2 times the amount relative to an arbitrary initial time) when the composition is heat-loaded at 40 ° (i.e. The composition is maintained at a temperature of 40 ° C) over a period of 28 days, preferably by a factor of not more than 1.5, preferably by a factor of not more than 1.3, and preferably the turbidity does not increase at all.
The pH of the liquid pharmaceutical composition changes (either by rise or fall, but usually by a decrease in pH) preferably by no more than 0.5 pH units when the composition is heat-loaded at 40 ° C (i.e., the composition is maintained at a temperature of 40 ° C) over a period of 28 days, preferably with a maximum of 0.2 pH units, preferably with a maximum of 0.1 pH units, most preferably the pH does not change at all (with a decimal accuracy).
Parameters under mechanical load exposure.
The amount (or concentration) of aggregates (preferably derived from adalimumab and preferably as determined by the SE-HPLC protocols defined herein) present in the liquid pharmaceutical composition preferably increases by at most a factor of 2 (i.e., 2 times the amount relative to an arbitrary starting time) when the composition is mechanically loaded (i.e. shaken according to the protocols given herein) over a period of 48 hours, preferably by no more than a factor of 1.5, preferably not more than a factor of 1.2, preferably not more than a factor of 1.1.
The amount (or concentration) of fragments (preferably derived from adalimumab and preferably measured by the bioassay protocols defined herein) present in the liquid pharmaceutical composition preferably increases by a maximum of a factor of 2 (i.e. 2 times the amount relative to an arbitrary onset time) when the composition is mechanically loaded (i.e. shaken according to the protocols given herein) over a period of 48 hours, preferably at most a factor of 1.5, preferably at most of a factor of 1.2, preferably at most of a factor of
1.1.
The turbidity (preferably measured by nephelometry in accordance with the protocols set forth herein) of the liquid pharmaceutical composition preferably increases by a maximum of a factor of 2 (i.e. 2 times the amount relative to an arbitrary initial time) when the composition is mechanically loaded (i.e., shaken according to the protocols given). herein) over a period of
Y4 hours, preferably by no more than a factor of 1.5, preferably not more than a factor of 1.2, preferably not more than a factor of 1.1, and preferably the turbidity does not increase at all.
The pH of the liquid pharmaceutical composition changes (either by rise or fall, but usually by a decrease in pH) preferably by no more than 0.5 pH units when the composition is mechanically loaded (i.e., shaken according to the protocols given herein). over a period of 48 hours, preferably with a maximum of 0.2 pH units, preferably with a maximum of 0.1 pH units, most preferably the pH does not change at all (with a decimal accuracy).
Parameters under exposure to light exposure.
The amount (or concentration) of aggregates (preferably derived from adalimumab and preferably as determined by the SE-HPLC protocols defined herein) present in the liquid pharmaceutical composition preferably increases by a maximum of a factor of 50 (i.e., 50 times the amount relative to an arbitrary starting time) when the composition is exposed to light (i.e., the composition is exposed to light in accordance with the protocols described herein, i.e., 7 hours at 765 W / m ² ), preferably by at most a factor 45, preferably by at most a factor of 35, preferably by at most factor 30.
The amount (or concentration) of fragments (preferably derived from adalimumab and preferably measured by the bioassay protocols defined herein) present in the liquid pharmaceutical composition preferably increases by a maximum of a factor of 4 (i.e. 4 times the amount relative to an arbitrary onset time) when the composition is light-exposed (i.e., the composition is exposed to light in accordance with the protocols described herein, i.e., 7 hours at 765 W / m ² ), preferably by a maximum of a factor of 3, preferably by a maximum of a factor of 2.5, preferably by a maximum of a factor of 2.
The turbidity (preferably measured by nephelometry in accordance with the protocols set forth herein) of the liquid pharmaceutical composition preferably increases by a maximum of a factor of 2 (i.e., 2 times the amount relative to an arbitrary initial time) when the composition is exposed to light (i.e., the composition is exposed to light). in accordance with the protocols described herein, i.e., 7 hours at 765 W / m ² ), preferably by no more than a factor of 1.5, preferably by no more than a factor of 1.2, and preferably the turbidity does not increase at all.
The pH of the liquid pharmaceutical composition is one
Y4 occurs (either by rise or fall, but usually by a decrease in pH), preferably with a maximum of 0.5 pH units when the composition is exposed to light (i.e., the composition is exposed to light in accordance with the protocols described herein, i.e. 7 hours at 765 W / m ² ), preferably with a maximum of 0.2 pH units, preferably with a maximum of 0.1 pH units, most preferably the pH does not change at all (with a decimal accuracy).
Parameters during exposure to freeze / thaw cycles.
The amount (or concentration) of aggregates (preferably derived from adalimumab and preferably as determined by the SE-HPLC protocols defined herein) present in the liquid pharmaceutical composition preferably increases by a maximum of a factor of 1.5 (i.e., 1.5 times the amount in relative to an arbitrary initial time) when the composition is subjected to five freeze / thaw cycles (i.e., the composition is frozen and thawed five times in accordance with protocols presented herein, i.e., -80 ° C to 20 ° C five times), preferably at most a factor of 1.2, preferably by no more than a factor of 1.1, preferably there is (substantially) no increase at all in the amount (or concentration) of aggregates.
Preferably, the amount (or concentration) of invisible particles or precipitates having a particle size below or equal to 25 microns present in the liquid composition increases by at most a factor of 4 (i.e., 4 times the amount relative to an arbitrary initial time) when the composition are subjected to five freeze / thaw cycles (i.e., the composition is frozen and quenched five times according to protocols described herein, i.e., -80 ° C to 20 ° C five times), preferably by a maximum of a factor of 3, preferably by a maximum of a factor of 2 , 5, preferably with not more than a factor of 2.2.
The amount (or concentration) of invisible particles or precipitates having a particle size below or equal to 10 microns present in the liquid composition preferably increases by a maximum of a factor of 4 (i.e., 4 times the amount relative to an arbitrary initial time) when the composition are subjected to five freeze / thaw cycles (i.e., the composition is frozen and quenched five times according to protocols described herein, i.e., -80 ° C to 20 ° C five times), preferably by not more than a factor of 3, preferably by not more than a factor of , 5, preferably with not more than one factor 2.2.
The amount (or concentration) of invisible particles or precipitates
Preferably, Y4 particles with a particle size below or equal to 25 microns present in the liquid composition increase by a maximum of a factor of 4 (i.e., 4 times the amount relative to an arbitrary initial time) when the composition is subjected to 5 freeze-thaw cycles. preferably with not more than a factor of 3, preferably with not more than a factor of 2.5, preferably with not more than one factor
2.2.
Preferably, the amount (or concentration) of invisible particles or precipitates having a particle size below or equal to 10 microns present in the liquid composition increases by at most a factor of 4 (i.e., 4 times the amount relative to an arbitrary initial time) when the composition subject to 5 freeze / thaw cycles, preferably by a maximum of a factor of 3, preferably by a maximum of a factor of 2.5, preferably by a maximum of a factor of
2.2.
Methods for stabilizing antibody.
In view of the aforementioned points in this subsection and the data reproduced in the Examples, there is also provided a method for stabilizing liquid adalimumab compositions (chemical and / or physical, optionally with respect to one or more of the aforementioned parameters / properties), comprising admixing adalumimab with a any relevant constituent necessary to form a liquid composition as defined herein. Various embodiments will preferably require mixing of various combinations of constituents, potentially in different amounts, and those skilled in the art can readily deduce such combinations and amounts by referring to the foregoing description of the liquid pharmaceutical composition. Such various combinations of constituents can stabilize liquid adalimumab compositions in various respects. For example, mixing adalimumab with the aforementioned ingredients to form a liquid pharmaceutical composition as defined herein can stabilize adalimumab by:
i) increasing adalimumab's protein unfolding temperature;
ii) inhibiting the formation of aggregates;
iii) inhibiting the formation of fragments iv) inhibiting the formation of invisible particles (either <25 microns or <10 microns);
DK 201800071 Y4
v) inhibiting turbidification;
vi) inhibiting pH changes;
vii) to inhibit photooxidation, and / or viii) to reduce instability after freeze / thaw cycles.
The generation, as such, provides a method for obtaining one, some, or all of the following beneficial advantages:
i) increased protein unfolding temperatures for adalimumab;
(il) inhibition of aggregate formation;
ill) inhibition of fragment formation;
iv) inhibition of formation of invisible particles (either <25 microns or <10 microns);
v) inhibition of turbidification;
vi) inhibition of pH changes;
(vii) photooxidation inhibition; and / or viii) reduced instability following freeze / thaw cycles;
wherein the method comprises preparing a liquid pharmaceutical composition of adalimumab as defined herein.
The liquid pharmaceutical compositions of the preparation preferably have a shelf life of at least 6 months, preferably at least 12 months, preferably at least 18 months, more preferably at least 24 months. The liquid pharmaceutical compositions of the preparation preferably have a shelf life of at least 6 months, preferably at least 12 months, preferably at least 18 months, more preferably at least 24 months, at a temperature of 2-8 ° C.
To enable the skilled person to optimize essential stability properties.
The new combination of constituents presented for use in liquid pharmaceutical compositions of the invention enables those skilled in the art to form (and, by reasonable judgment, fine-tune) compositions which exhibit comparable or improved properties to those of the prior art. In particular, this specification now provides all necessary tools for optimizing the formulation stability to our skilled artisan, particularly for the purpose of optimizing one or more among: aggregation inhibition, fragmentation, protein extract 201800071 Y4 folding, precipitation, pH slip and oxidation (especially photooxidation) . In addition, those skilled in the art are guided to achieve such optimizations (by varying the compositions by discretion) and to minimize harmful side effects along the way. The present disclosure will enable the person skilled in the art to practice its entire scope of protection to form all kinds of specific compositions which exhibit comparable or improved properties to those of the prior art, and this can be achieved using fewer ingredients.
Particular embodiments
In one embodiment, the liquid pharmaceutical composition comprises:
adalimumab;
a histidine buffer agent (e.g., histidine) (or histidine buffer system);
a sugar stabilizer (e.g., trehalose); and a surfactant (e.g., polysorbate 80).
In one embodiment, the liquid pharmaceutical composition comprises:
adalimumab;
a histidine buffer agent (e.g., histidine) (or histidine buffer system);
a sugar stabilizer (e.g., trehalose);
a tonizing agent (e.g., sodium chloride); and optionally a surfactant (e.g., polysorbate 80).
In one embodiment, the liquid composition comprises adalimumab, histidine buffer agent (or buffer system), and a sugar stabilizer in a molar ratio of 1: 14-40: 288-865, respectively. In one embodiment, the liquid composition comprises adalimumab, histidine buffer agent (or buffer system), sugar stabilizer, and a tonic agent in a molar ratio of 1: 14-40: 288-865: 28-576, respectively.
In one embodiment, the liquid composition comprises adalimumab, histidine buffer agent (or buffer system), and a sugar stabilizer in a mole ratio of 1: 14-40: 548-605, respectively. In one embodiment, the liquid composition comprises adalimumab, histidine buffer agent (or buffer system), sugar stabilizer, and a tonic agent in a mole ratio of 1: 14-40: 548-605: 1 15-173, respectively.
DK 201800071 Y4
In one embodiment, the liquid composition comprises adalimumab, histidine buffer agent (or buffer system) and trehalose at a molar ratio of 1: 5.7-145: 288-865, respectively. In one embodiment, the liquid composition comprises adalimumab, histidine buffer agent (or buffer system), trehalose and sodium chloride in a mole ratio of 1: 5.7-145: 288865: 28-576, respectively.
In one embodiment, the liquid composition comprises adalimumab, histidine buffer agent (or buffer system), and trehalose at a molar ratio of 1: 14-40: 548-605, respectively. In one embodiment, the liquid composition comprises adalimumab, histidine buffer agent (or buffer system), trehalose, and sodium chloride in a molar ratio of 1: 14-40: 548605: 1 15-173, respectively.
In one embodiment, the liquid composition comprises adalimumab, histidine buffer agent (or buffer system) and trehalose at a molar ratio of 1: 28.8: 576, respectively. In one embodiment, the liquid composition comprises adalimumab, histidine buffer agent (or buffer system), trehalose and sodium chloride in a molar ratio of 1: 28.8: 576: 144, respectively.
In one embodiment, the liquid composition comprises adalimumab, histidine buffer agent (or buffer system) and trehalose at a molar ratio of 25-75: 0.31-7.8: 15-140, respectively. In one embodiment, the liquid composition comprises adalimumab, histidine buffer agent (or buffer system), trehalose, and sodium chloride in a molar ratio of 1: 25-75: 0.31-7.8: 15-140: 0.5-12, respectively.
In one embodiment, the liquid composition comprises adalimumab, histidine buffer agent (or buffer system), and trehalose in a molar ratio of 45-55: 0.77-2.2: 65-72, respectively. In one embodiment, the liquid composition comprises adalimumab, histidine buffer agent (or buffer system), trehalose, and sodium chloride in a molar ratio of 45-55: 0.772.2: 65-72: 2.7-3.1, respectively.
In one embodiment, the liquid composition comprises adalimumab, histidine buffer agent (or buffer system) and trehalose at a molar ratio of 50: 1.55: 68, respectively. In one embodiment, the liquid composition comprises adalimumab, histidine buffer agent (or buffer system), trehalose and sodium chloride in a molar ratio of 50: 1.55: 68: 2.9,
DK 201800071 Y4 respectively.
Any of the aforementioned embodiments with respect to mole and / or weight ratios of the various constituents can be further defined by reference to the (substantial or complete) absence of small amounts of constituents such as arginine, amino acids other than histidine, surfactants (optionally with the exception of polysorbate 80) and / or phosphate buffer agents / systems as defined anywhere herein.
Those skilled in the art will appreciate that the buffering agent (e.g., histidine) or the buffer system (e.g., histidine / imidazolium-histidine) of any of the aforementioned embodiments may be directly incorporated into the compositions or may be formed in situ, e.g. an acid-base reaction, preferably by reacting a corresponding acid to the buffer agent (e.g., the imidazolium form of histidine, be it a preformed salt such as histidine hydrochloride or the imidazolium form formed by dissolving free histidine) with a base (e.g. sodium hydroxide). Whatever method is used to provide or produce the buffer or buffer system, the resulting composition ultimately has a suitable balance between the buffer and any corresponding acid / base to obtain the desired pH value.
In one embodiment, the liquid pharmaceutical composition comprises the following: adalimumab;
a histidine buffer agent (e.g., histidine) (or histidine buffer system);
a sugar stabilizer (eg trehalose) a tonic (eg sodium chloride);
optionally a surfactant (e.g., polysorbate 80); and water (of injection purity);
wherein the composition:
o is (substantially or completely) free of arginine (preferably L-arginine) or comprises arginine at a concentration not exceeding 0.1 mM;
o is (substantially or completely) free of amino acids other than histidine or comprises one or more amino acids other than histidine at a (total) concentration not exceeding 0.1 mM;
o is (substantially or completely) free of surfactant
Y4 substances with the possible exception of polysorbate 80 or comprising one or more of the aforesaid surfactants (optionally exclusive polysorbate 80) at a (total) concentration not exceeding 1 mM; and / or o are (substantially or completely) free of phosphate buffer agents (e.g., sodium dihydrogen phosphate, disodium hydrogen phosphate) or comprise a phosphate buffer system at a concentration not exceeding 0.1 mM.
In one embodiment, the liquid pharmaceutical composition comprises the following:
Adalimumab (preferably at a concentration as defined herein);
to 14 mM histidine buffer agent (e.g., histidine) (or histidine buffer system);
100 to about 300 mM sugar stabilizer (eg trehalose);
to about 200 mM tonizing agent (e.g., sodium chloride); and water (of injection purity);
wherein the composition:
o has a pH of between 6.3 and 6.7 (e.g., 6.4);
o is (substantially or completely) free of arginine (preferably L-arginine) or comprises arginine at a concentration not exceeding 0.1 mM;
o is (substantially or completely) free of amino acids other than histidine or comprises one or more amino acids other than histidine at a (total) concentration not exceeding 0.1 mM;
o are (substantially or completely) free of surfactants, with the exception of polysorbate 80, or comprise one or more of said surfactants (optionally exclusive polysorbate 80) at a (total) concentration not exceeding 1 mM; and / or o are (substantially or completely) free of phosphate buffer agents (e.g., sodium dihydrogen phosphate, disodium hydrogen phosphate) or comprise a phosphate buffer system at a concentration not exceeding 0.1 mM.
In one embodiment, the liquid pharmaceutical composition comprises the following:
To about 75 mg / ml adalimumab;
to about 50 mM histidine (or histidine buffer system);
00 to about 300 m M trehalose;
to about 200 mM sodium chloride; and water (of injection purity);
wherein the composition:
o has a pH of between 6.3 and 6.5;
o is (substantially or completely) free of arginine (preferably L-arginine) or comprises arginine at a concentration not exceeding 0.1 mM;
o is (substantially or completely) free of amino acids other than histidine or comprises one or more amino acids other than histidine at a (total) concentration not exceeding 0.1 mM;
o are (substantially or completely) free of surfactants or comprise one or more surfactants at a (total) concentration not exceeding 1 mM; and / or o are (substantially or completely) free of phosphate buffer agents (e.g., sodium dihydrogen phosphate, disodium hydrogen phosphate) or comprise a phosphate buffer system at a concentration not exceeding 0.1 mM.
In one embodiment, the liquid pharmaceutical composition comprises the following:
to about 55 mg / ml adalimumab;
to 14 mM histidine (or histidine buffer system);
190 to 210 mM trehalose;
to 60 mM sodium chloride; and water (of injection purity);
wherein the composition:
o has a pH of between 6.3 and 6.5;
o is (substantially or completely) free of arginine (preferably L-arginine) or comprises arginine at a concentration not exceeding 0.001 mM;
o is (substantially or completely) free of amino acids other than histidine or comprises one or more amino acids other than histidine at a (total) concentration not exceeding 0.001 mM;
Are (substantially or completely) free of surfactants or comprise one or more surfactants at a (total) concentration not exceeding 0.0001 mM; and / or is (substantially or completely) free of phosphate buffer agents (e.g., sodium dihydrogen phosphate, disodium hydrogen phosphate) or comprises a phosphate buffer system at a concentration not exceeding 0.001 mM.
In one embodiment, the liquid pharmaceutical composition comprises the following:
mg / ml adalimumab;
mM histidine (or histidine buffer system);
200 mM trehalose;
mM sodium chloride;
1.0 mg / ml polysorbate 80; and water (of injection purity);
wherein the composition:
o has a pH of 6.4;
o is free of arginine;
o is free of amino acids other than histidine;
o is free from surfactants; and o is free of phosphate buffering agents / buffer systems.
Preferably, the liquid pharmaceutical composition consists essentially of:
to about 75 mg / ml adalimumab;
to about 50 mM histidine (or histidine buffer system);
100 to about 300 mM trehalose;
to about 200 mM sodium chloride; and water (of injection purity);
o where the composition has a pH of between 6.3 and 6.5.
Preferably, the liquid pharmaceutical composition consists essentially of:
to about 60 mg / ml adalimumab;
to about 15 mM histidine (or histidine buffer system);
175 to about 225 mM trehalose;
to about 75 mM sodium chloride; and
DK 201800071 Y4 water (of injection purity);
o where the composition has a pH of between 6.3 and 6.5.
Preferably, the liquid pharmaceutical composition consists essentially of:
mg / ml adalimumab;
mM histidine (or histidine buffer system);
200 mM trehalose;
mM sodium chloride; and water (of injection purity);
o where the composition has a pH of 6.4.
The liquid pharmaceutical composition may be as set forth in any of the foregoing embodiments, except that the absence or low content of ingredients such as arginine, amino acids, surfactants (optionally with the exception of polysorbate 80) and phosphate buffer agents / systems rather than being defined by reference to concentrations (i.e., molarity) may be defined instead by reference to corresponding molar ratio of the component to the buffer agent / buffer system; corresponding component weight ratio of adalimumab or corresponding component molar ratio of adalimumab. The person skilled in the art will readily deduce for each ingredient from the relevant section of this specification the specific ingredient, which mole and weight ratios correspond to which concentrations, since the relevant mole and weight ratios are listed to correspond to the respective given concentrations . For example, in the case of arginine, the eventual concentrations of "at most 0.1 mM, more preferably at most 0.01 mM, most preferably at most 0.001 mM", respectively, correspond to a mole ratio of arginine to buffer of at most 1: 150 .. more preferably not more than 1: 1500, most preferably not more than 1: 15,000 ", to" a weight ratio of arganine to adalimumab of not more than 1: 3000 ... more preferably not more than 1: 30,000 .... most preferably not more than 1: 300,000 " , and "to a mole ratio of arginine to adalimumab of at most 1: 3.75. more preferably at most 1: 37.5, most preferably at most 1: 375." The same correspondences apply to amino acids, surfactants and phosphate buffer agents / systems.
DK 201800071 Y4
Process for the preparation of a liquid pharmaceutical composition
The preparation provides a process for producing a liquid pharmaceutical composition, preferably as defined herein. The process preferably comprises mixing together any relevant constituents required to form a liquid pharmaceutical composition as defined herein in any order considered appropriate. Those skilled in the art can rely on the Examples or techniques well known in the art for forming liquid pharmaceutical compositions (especially those for injection by syringe). Different embodiments will preferably require mixing of various combinations of constituents, potentially in different amounts. Those skilled in the art can readily deduce such combinations and amounts by referring to the foregoing description of the liquid pharmaceutical composition.
Preferably, the method comprises mixing the relevant constituents in preferably a diluent (e.g., water), preferably such that all constituents (substantially or completely) dissolve in the diluent.
The process may include first preparing a premix (or pre-solution) of some or all of the ingredients (optionally with some or all of the solvent) without adalimumab, and then adalimumab itself (optionally with or pre-dissolved in any of the diluent) may be mixed in the premix (or pre-solution) ) to obtain the liquid pharmaceutical composition or a composition to which final ingredients are subsequently added to give the final liquid pharmaceutical composition. Most preferably, the premix contains all the components except adalimumab and optionally also some diluent (which can be used to pre-dissolve adalimumab), preferably such that adalimumab is added to a mixture which offers optimal stabilization of adalimumab. Preferably, said premix is prepared at the desired pH for the final liquid pharmaceutical formulation.
The method preferably comprises forming a buffer system, preferably a buffer system comprising a buffer means as defined herein.
DK 201800071 Y4
The buffer system is preferably formed in a premix prior to the addition of adalimumab, although the buffer system may be formed in the presence of adalimumab. The buffer system can be formed by simply mixing the buffering agent (supplied ready-made) with its corresponding acid / base (preferably in appropriate relative amounts to obtain the desired pH value - this can be determined by one skilled in the art either theoretically or experimentally). In the case of a histidine buffer system, this results in a mixture of histidine with an imidazolium form of histidine (eg histidine hydrochloride). Alternatively, the buffer system may be formed by the addition of a strong acid (e.g., HCl) to the buffer (e.g., histidine) to form in situ the corresponding acid / base (e.g., the imidazolium form of histidine) to the buffer (again, preferably in appropriate relative amounts to obtain the desired pH). Alternatively, the buffer system may be formed by the addition of a strong base (e.g., sodium hydroxide) to the corresponding acid / base to the buffering agent (or to the buffering agent itself where it forms said corresponding acid / base in a dynamic equilibrium, such as after solution). in situ to form the buffer (again preferably in appropriate relative amounts to obtain the desired pH). The pH value of the premix of liquid pharmaceutical composition can be adjusted after estimation by adding the required amount of strong base or special acid or even a quantity of buffering agent or corresponding acid / base.
In certain embodiments, the buffer agent and / or buffer system is distilled as a separate mixture and the buffer system is transferred to a precursor of the liquid pharmaceutical composition (comprising some or all of the components except the buffer agent and / or buffer system, preferably comprising adalimumab and potentially only adalimumab) ( for example using diafiltration until the appropriate concentration or osmolality is reached). Additional excipients may then be added if necessary to form the final liquid pharmaceutical composition. The pH can be adjusted once or before all the ingredients are present.
Any, some or all of the constituents may be pre-dissolved or premixed with a diluent prior to mixing with other constituents.
The final liquid liquid composition can be filtered,
Preferably to remove particulate matter. Suitable filtration is done through filters of the size below or equal to 1 μm, preferably in the size of 0.22 μm. Preferably, the filtration is done through either PES filters or PVDF filters, preferably 0.22 μm - PES filters.
The preparation also provides a liquid pharmaceutical composition which is obtainable by, obtained by, or obtained directly by the process of preparation described herein.
Empty the Disassembly Densing Device
The preparation provides a drug dispensing device comprising a liquid pharmaceutical composition as defined herein. The drug dispensing device preferably comprises a chamber in which the pharmaceutical composition is present. Preferably, the drug dispensing device is sterile.
The drug dispensing device may be a vial, ampoule, syringe, injection pen (e.g., substantially comprising a syringe) or intravenous bag. Most preferably, the drug dispensing device is a syringe, preferably an injection pen. The syringe is preferably a glass syringe. The syringe preferably comprises a needle, preferably a 29G ^1/2 inch needle.
The invention provides a process for preparing a drug dispensing device, preferably as defined herein, wherein the method comprises incorporating a liquid pharmaceutical composition as defined herein into a drug dispensing device. Such preparation typically comprises loading the liquid pharmaceutical composition as defined herein onto a syringe, preferably via a needle attached thereto. The needle can then be removed, replaced or remain.
According to one aspect of the manufacture, there is provided a drug dispensing device obtainable by, obtained by or obtained directly by the method of preparation defined herein.
Packing
The preparation provides a package comprising a liquid pharmaceutical composition as defined herein. Preferably, the package comprises a drug dispensing device as defined herein, for DEK 201800071 Y4, several drug dispensing devices gradually. The package may comprise any suitable container for accommodating one or more drug dispensers.
The process provides a process for preparing a package which comprises incorporating a liquid pharmaceutical composition as defined herein into a package. Preferably, this is accomplished by incorporating the liquid pharmaceutical composition into one or more drug dispensing devices and then incorporating one or more pre-filled drug dispensing devices into a container contained in the package.
The manufacture provides a gasket which is obtainable by, obtained or directly obtained by a method of preparation defined herein.
Set of parts
The invention provides a set of parts comprising a drug dispensing device (without the liquid pharmaceutical composition incorporated therein), a liquid pharmaceutical composition as defined herein (optionally contained in a separate package or container) and optionally a set of instructions for administration (e.g. subcutaneous) of the liquid pharmaceutical composition. The user may then fill the drug dispensing device with the liquid pharmaceutical composition (which may be contained in a vial or ampoule or the like) prior to administration.
Applications of pharmaceutical liquid composition or methods of treatment
According to one aspect of the invention, there is provided a method of treating a disease or medical disorder; a liquid pharmaceutical composition for use in treatment: use of a liquid pharmaceutical composition for the manufacture of a medicament for the treatment of a disease or disorder; a method of treating a tumor necrosis factor-alpha (TNF-α) -related autoimmune disease; a liquid pharmaceutical composition for use in the treatment of a tumor necrosis factor-alpha (TNF-α) -related autoimmune disease; use of a liquid pharmaceutical composition for the manufacture of a medicament
DK400071 Y4 portion for the treatment of a tumor necrosis factor-alpha (TNF-α) -related autoimmune disease; a method of treating rheumatoid arthritis, psoriatic arthritis, Bechterew's disease, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and arthritis; a liquid pharmaceutical composition for use in the treatment of rheumatoid arthritis, psoriatic arthritis, Bechterew's disease, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis, and childhood arthritis; and use of a liquid pharmaceutical composition for the manufacture of a medicament for the treatment of rheumatoid arthritis, psoriatic arthritis, Bechterew's disease, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis, and rheumatoid arthritis, as defined herein.
The liquid pharmaceutical compositions defined herein can be used to treat any or more of the aforementioned diseases or medical disorders. In a particular embodiment, the liquid pharmaceutical compositions are used to treat rheumatoid arthritis, preferably Crohn's disease and psoriasis.
The liquid pharmaceutical compositions are preferably administered parenterally, preferably via subcutaneous injection.
EXAMPLES
Materials and equipment
The following materials were used to prepare formulations described in the following examples:
Ingredient Adalimumab DS arginine monohydrochloride aspartic acid Citric dibasicnatriumphosphatdihydrat histidine lysine hydrochloride mannitol monobasicnatriumphosphatdihydrat Poloxamer 188 Polysorbate 80
DK 201800071 Y4
Sodium chloride
Sodium
Sodium hydroxide solution 30%
trehalose dihydrate
WFI
The following disposable equipment and material were used in the examples and screening experiments as follows.
Equipment Code Supplier Eppendor tubes (0.5 mL, 1.5 mL, 2.0 mL) REACH Eppendorf Falcon 352096 (15 mL), 352070 (50 mL) polypropylene tube Becton Dickinson PES membrane (0.22 µm) filter unit MillexGP Express PES membrane REF SLGP033RS Millipore PETG bottles 3420-1000, 3420-0500, 2019-0250, 3420-0125,3420-0060,2019-0030 Nalgene
The following packaging was used in the Examples and Screening Experiments 5 as follows.
Equipment Code Supplier DIN2R Type I glass vials 0212060.6112 11200000A Nuova Ompi 1 mL stops S2-F451 RSV; D 21-7S RB2-40 Daikyo Seiko, LTD 13mm flip-off cap 12000350 MS-A
The following packaging was used in the examples and screening experiments as follows.
Equipment Against. Producer Analytical weights AX205, PG2002-S Mettler Toledo Benchtop xenon instrument Suntest CPS + Atlas Calibrated pipettes P20, P100, P200, P1000 Gilson HPLC Alliance Waters iCE280 Fixed IEF Analyzer Convergent Bioscience osmometer Osmomat 030 / D Gonotec PCR 7500 Fast Real-Time AB Applied Biosystem
DK 201800071 Y4
pH meters Seven Multi Mettler Toledo refrigerators + 2-8 ° C Angelantoni Software Design Expert ver. 7.1.5 Stat-Ease, Inc. Thermostatic cabinets + 25 ° C, + 40 ° C Angelantoni turbiditor 2100AN IS Hach Lange UV Spectrophotometer Lambda 35 Perkin Elmer
Analytical techniques and protocols
The following analytical protocol procedures were used in the Examples and Screening Experiments, as follows, for the reasons given in the table below5 for:
Method No. Analytical method Purpose of testing 1 Bioanalyzer purity 2 DSF The unfolding 3 ICE280 Profiles of isoforms 4 OD protein 5 SE-HPLC Aggregatbestemmelse 6 nephelometry turbidity 7 osmolality Osmolality of solution 8 pH pH determination 9 Invisible particles particle Counting
The protocols for each of the above analytical methods are described below, and reference in the examples and screening experiments to any of such analytical methods and screening experiments has been used using these protocols.
1. Purity - Bioanalyzer
A 2100 Bioanalyzer was used. Minutes are provided in the current instruction manuals. However, the protocols are further adjusted as follows.
solutions:
Gel-Dye Mix (staining solution):
DK 201800071 Y4
Add 25 μΙ 230plus color concentrate to a protein 230plus gel matrix tube. Thoroughly swirl and centrifuge the tube for 15 seconds. Transfer to a spin filter and spin at 2500rpm for at least 20min. The solution is ready to use. Store the solution at + 5 ± 3 ° C for a maximum of 4 weeks.
destaining:
Pipette 650µΙ gel matrix into a spin filter. Centrifuge at 2500rpm for at least 25 minutes. Store the solution at + 5 ± 3 ° C for a maximum of 4 weeks.
Sample Buffer:
It is recommended to divide the 200 μΙ sample buffer into measured portions of 25 μΙ and re-freeze a measured portion for each chip. Store the sample buffer stock solution and measured portions at -20 ° C, no longer than the expiration date specified by the supplier.
Maleimide strain solution:
Dissolve 23.4 mg of maleimide in 1 ml of MilliQ water (0.24M). Shake the solution thoroughly. Subsequently, the solution is diluted 1: 4 with MilliQ water. (e.g., 50 μΙ stock solution + 150 μΙ MilliQ). The final concentration of the diluted maleimide solution is 60mM. (As data on the stability of this solution are not yet available, it must be freshly prepared for each assay).
OTf solution:
For analysis of Adalimumab samples, the reducing solution must be prepared with 1 M DTT, therefore, 1 54.0 mg of DTT is dissolved in 1 ml of MilliQ water.
Non-reducing solution:
Add 1 μΙ MilliQ water to a metered sample buffer portion (25 μΙ) and spin for 5 seconds. Use the non-reducing solution on the same day it was prepared.
DK 201800071 Y4
Reducing resolution:
Add 1 μΙ DTf solution to a metered sample buffer portion (25 μΙ) and spin for 5 seconds. Apply the reducing solution on the same day as it was prepared.
Sample preparation:
Samples with a concentration range between 2.4 and 3 mg / ml are analyzed.
If necessary, the samples can be diluted to the desired concentration with Milli Q water.
Samples are prepared in accordance with the Reagent Kit Guide using reducing and non-reducing sample buffers according to the Reagent Kit Guide and also as described above. Contrary to the instructions, it is strongly recommended to use larger volumes to obtain reproducible and accurate results. An example of how the marker and samples are prepared are given below:
Sample preparation Resolution; reducing and non-reducing conditions
reagent Volume, μΙ Total volume, μΙ Sample diluted to 3 mg / ml 3μΙ 6 μΙ Sample Buffer (Reducing or Non-Reducing) 2 μΙ Maleimide solution 1 μΙ Samples should be well mixed (with vortex shaker) and centrifuged. All samples and the marker are heated at 70 ° C for 5 minutes. MilliQ water 84 μΙ 90 μΙ Shake well and spin; fill 6 μΙ, the entire sample and marker
DK 201800071 Y4
Note 1: For those IPCs whose concentration is between 2.4 mg / ml and 3.0 mg / ml, the sample preparation follows the table above, except for the volume of Mi 11 iQ water added after sample heating, which is calculated for at a final protein concentration of 0.1 mg / ml.
An example of a sample having a concentration of between 2.4 and 3.0 mg / ml is given below:
Sample preparation Resolution; reducing and non-reducing conditions
reagent Volume, μΙ Total volume, μΙ Sample diluted to 3 mg / ml 3μΙ 6 μΙ Sample Buffer (Reducing or Non-Reducing) 2 μΙ Maleimide solution 1 μΙ Samples should be well mixed (with vortex shaker) and centrifuged. All samples and the marker are heated at 70 ° C for 5 minutes. MilliQ water 72 μΙ 78 μΙ Shake well and spin; fill 6 μΙ, the entire sample and marker
Note 2: All wells must be filled. If the number of samples is lower than the number of wells, the empty wells can be used for extra duplicate or blank samples.
Preparation of the system and chip:
To clean the system before and after an analysis, the Electrode Cleaner is filled with 600 µΙ MilliQ water and placed in the Agilent 2100 Bioanalyzer, the lid is closed and the system shuts down. Nothing further is required.
Align the base plate of the chip-priming station to position A and the spray clip to its intermediate position.
Preparing the chip
DK 201800071 Y4
Preparation of the system
Insert a new protein chip into the priming station
Pipette 12 μΙ Gel-Dye mixture into the well labeled G (top right)
Set the plunger to 1 ml and close the chip priming station
Press the plunger down until it is held by the chip
Wait 60 seconds and then release the chip
Wait 5 seconds and slowly withdraw the plunger to the 1 ml mark
Open the chip priming station
Remove the solution in this well
Pipette 12 μΙ Gel-Dye mixture into the well labeled G (top right) and into all other wells labeled G
Pipette 12 μΙ of decolorization solution into the well labeled DS
Marker and sample application:
Transfer 6 μΙ_ of each sample to the sample well and likewise 6 μΙ_ of the marker into the 5 well specified, which is clearly indicated by a marker symbol. Place the chip in the Agilent 2100 Bioanalyzer and start the analysis within 5 min.
Example of test set
Well Sample Quantity, μΙ 1 Blank 6 2 Blank 6 3 Unknown sample 1, rep 1 6 4 Unknown sample 1, rep 2 6 5 Unknown sample 2, rep 1 6 6 Unknown sample 2, rep 2 6 7 Unknown sample 3, rep 1 6
DK 201800071 Y4
8 Unknown sample 3, rep 2 6 9 Current reference material, rep 1 6 10 Current reference material, rep 2 6 Marker Marker 6
Data analysis and evaluation of results:
To get results, the following steps must be performed at least:
• Place the chip in the designated location and close the lid.
• In instrument, select Assay - Electrophoresis- Protein- Protein 230 Plus.
• Press START to start the analysis, which is completed within 30 minutes.
• Raw data is displayed by pressing Data Analysis, which lists all experiments performed that day. Press the desired test and select it • The gel generated from the selected trial opens automatically.
• Data can be displayed as an electropherogram or gel-like image.
Detailed information on the integration of peaks in the electropherogram (for purity data) is provided in the manual of the software. The purity of the sample is given by the system by automatic integration, but if necessary manual integration can be used.
results:
Under non-reducing conditions, the results are given as% Purity (purity) and% LMW (sum of peaks before monomer).
Under reducing conditions, the results are given as% Purity as the sum of the heavy and light chain.
The indicative molecular weight is given in the table below:
DK 201800071 Y4
Indicative molecular weight of Adalimumab
conditions Result KDa Non-reducing monomer 151 reducing LC 27 HC 58
2.Foldout temperature - DSF
DSF (differential scanning fluorimetry) was performed as follows:
microliters of Sypro Orange (Orange protein gel color, cod. S6650, Life Technologies) pre-diluted 500-fold in water of injection was added 20 microliters of drug product solution. When adding Sypro Orange, DP solutions (samples in triplicate) are filled into 96-well plates (MicroAmp Fast 96W Reaction Plate 0.1 ml, cod. 4346907). The plates are then sealed with a protective transparent cover (MicroAmp Optical Adhesive Film, cod. 431 1 971) and then centrifuged to remove air bubbles. The plates are then loaded into the 7500 Fast Real-Time AB Applied Biosystem PCR system and scanned for emission profiles at temperatures from room temperature to 90-100 ° C. Fluorescence emission intensity dependence on temperature is a curve that typically shows a turning point / stop at denaturation temperature, and is a parameter used to compare the various compositions.
3. Profile of isotherms - iCE280 cl EF at iCE280 (profile of isotherms): After purification and removal of salts by centrifugation in an Amicon Ultra-4 centrifuge (cut off 10 kDa), the samples were pre-diluted to a concentration of 5.0 mg / ml with purified water. A next dilution was then made to 1.0 mg / ml with a solution consisting of: methylcellulose, Pharmalyt 5-8 (GE Healthcare), Pharmalyt 8-10.5 (GE Healthcare), low-pl marker 7.05 (Protein Simple ), high-pl marker 9.50 (Protein Simple) and purified water. After dilution, the samples were centrifuged at 10000 rpm for 3 minutes. An additional centrifugation step (2 minutes at 7000 rpm) is then performed with 150 microliters of each sample transferred to glass inserts, cl EF (capillary isoelectric focusing) was performed with the iCE280 system with Protein Simple,
DK 201800071 Y4 using capillary cassettes Fc with 100 micron ID coating and a total length of 50 nm (Cat. No. 101700/101701 by Protein Simple). Separation of the various isoforms is done using 100 mM sodium hydroxide (in 0.1% methylcellulose) as cathodic solution and 80 mM o-phosphoric acid (in 0.1% methylcellulose) as anodic solution. The electropherogram appears at 280 nm at pre-focusing and focusing times of 1 and 6 minutes, respectively, at a voltage of 1500 V (pre-focusing) and 3000 V (focusing).
4. Protein content - OD
OD (protein content) measurements were performed on samples which were pre-diluted gravimetrically (three independent dilutions were prepared) with relevant buffer or placebo from initial concentrations to approximately 10 mg / ml. The diluted solutions were tested for absorbance at 280 and 320 nm in 0.1 cm long quartz incubators, at room temperature, with a double-beam spectrophotometer (Lambda35 from Perkin Elmer). The value of 1.35 was used as the molar extinction coefficient for Adalimumab.
5. Unit Determination - SE-HPLC
The samples were diluted with DPBS 1X to a concentration of 0.5 ml and injected (20 microliters of injection volume) into a TSK gel Super SW3000 4.6mm ID X 30.0 cm cod.18675 column from Tosoh while maintaining isocratic conditions (mobile phase: 50mM sodium phosphate + 0.4M sodium perchlorate, pH 6.3 ± 0.1). UV detection was performed at 214 nm at a flow rate of 0.35 ml. Each analytical cycle had a duration of 15 minutes. Prior to analysis, samples were stored at 2-8 ° C in the Waters Alliance HPLC system autosampler used for this analysis.
6. Turbidity - nephelometry
Turbidity was evaluated by nephelometric (the effect based on light diffusion effect caused by particles with dimensions typically <1 micron) measurements performed with a turbidimeter 21 00ΑΝ IS Turbidimeter from Hach at room temperature. Minimum quantities of 3 ml solution were added to glass cuvettes with reduced voDK 201800071 Y4 lumen and tested for diffusive power after prior calibration of the instrument with a number of standard solutions (0.1 - 7500 NTU).
7. Determination of Osmolality - Osmolality
Osmolality was measured based on the cryoscopic characteristics of the solutions. The analyzes were performed with an Osmomat 030-D from Gonotech, where 50 microliters of the samples were defeated. The freezing temperature depends on the osmolality of the solution (i.e., the presence of agents dissolved such as salts, sugars, other ionic and non-ionic compounds, etc.).
8. pH determination - pH pH was determined by potentiometric measurements at room temperature with Mettler Toledo Seven Multi pH meter.
9.Part I count - Non-particulate particles
The samples were diluted 5-fold with purified water to a final volume of 25 ml. The number of particles is determined at room temperature with PAMAS SVSS from Aminstruments by collecting four independent runs and taking an average of the results from each dimensional fraction of interest.
Example 1 - Formulations for first formulation screening
The following first set of formulations (often referred to as DoE1 formulations herein) are shown below in Table 1.
Table 1: List of DoE1 formulations for subsequent screening experiment 1
Form Salt (NaCl) Buffer Type Wife (mM) (10 mM) pH
stabilizer
histidine
6.0
Trehalose dihydrate (200 mM)
DK 201800071 Y4
19 50 histidine 6.0 Lysine Hydrochloride (100 mM) 20 100 histidine 6.0 Mannitol (200 mM) 21 50 histidine 6.2 Lysine Hydrochloride (100 mM) 22 50 histidine 6.2 Arginine monohydrochloride + aspartic acid (80 mM + 20 mM) 23 75 histidine 6.2 Trehalose dihydrate (200 mM) 24 25 histidine 6.4 Mannitol (200 mM) 25 100 histidine 6.4 Trehalose dihydrate (200 mM)
The formulations in Table 1 were prepared starting with a preformulated surfactant-free DS material.
A measured portion of DS has been diafiltered with a 10 mM histidine buffer at pH 6.0 until a three-fold volume yield with the buffer was obtained. Then, the indicated excipients were added to the buffer-exchanged DS materials and the pH adjusted.
After exchange buffer Start-DSvolume Start DSkoncentration Processed Protein (mg) Final volume (ml) Final concentration (mg / ml) Recovered Protein (mg) Yield(%) osmolality(MOsm / kg) histidine 200 63.3 12660 200 56.9 11280 90 23
easily to the target by adding a dilute solution of sodium hydroxide. Each formulation was filtered through 0.22 μm PES filters.
In Table 2, the results with respect to material recovery and osmolality of the three buffer-exchanged DS materials are given.
Table 2: Recovery and osmolality of DS materials after buffer exchange
There was a good recovery of the histidine buffer system (<90%). Values of osmolality indicate that a satisfactory degree of buffer exchange has been achieved with a minimal residue of substances derived from the original DS.
Example 2 - Formulations for second formulation screening
DK 201800071 Y4
The following second set of formulations (often referred to as DoE2 formulations herein) are shown below in Table 3 (as derived from Table 4 below again).
Table 1: List of DoE2 formulations for next Screening Experiment 2 (formulations derived from those shown in Table 4, with the additional surfactant as indicated)
formulations Polysorbate 80 concentration (mg / mL) 0 0.5 1 Form 7 (derived from Form C, Table 4) X - - Form 8 (derived from Form C, Table 4) - X - Form 9 (derived from Form C, Table 4) - - x
Table 4: Formulation prototype derived from the DoE1 screening
Form Salt (NaCl) mM Buffer type (10 mM) pH stabilizer C 100 histidine 6.4 Trehalose dihydrate (200 mM)
The DoE2 formulations (Table 3) were prepared starting with a preformulated surfactant-free DS material.
Three measured portions of DS have been diafiltered until a three-fold volume yield is obtained. Subsequently, the required excipients have been added to the buffer-exchanged DS materials and the pH has been adjusted to the target value by the addition of a dilute sodium hydroxide solution. Each formulation was filtered through 0.22 µm PES filters.
Table 5 presents the osmolality and turbidity results for buffer-exchanged DS materials.
The osmolality values (<40 mOsm / kg) indicated the satisfactorily achieved degree of buffer exchange with a minimal residue of substances derived from the original DS.
Table 5: Osmolality increases turbidity of DS materials after buffer depletion
DK 201800071 Y4
buffer turbidity(NTU) osmolality(MOsm / kg) histidine 50 26
Example 3 - Comparative formulations for both first and second screening
For comparison and control purposes, three reference formulations were prepared or obtained, including Ref-1 (Humira® composition manufactured by applicant); Ref-2 (RMP US - Hum ira®, US commercial drug product); and Ref-3 (RMP EU - Humira®, EU commercial pharmaceutical product). All of these reference formulations have the composition shown in Table 6.
Table 6: Composition of Humira DP
Ingredient Amount per container (mg) (fill volume = 0.8 ml) Amount (mg / ml) adalimumab 40 50 Citric 1.04 1.3 Dibasic sodium phosphate dehydrate 1.22 1.53 mannitol 9.6 12 Monobasic sodium phosphate dehydrate 0.69 0.86 Polysorbate 80 0.8 1 Sodium chloride 4.93 6.16 Sodium 0.24 0.3 WFI and sodium hydroxide q.b. for adjusting the pH to 5.2 q.b. to adjust pH 5.2
SCREENING
An initial formulation screening (DoE1) led to the determination of various factors (e.g., pH, presence of NaCl, excipient type) responsible for protein stability, and ultimately selection of formulations to be pursued in a second screening. (DoE2), which sought to fine-tune the formulations and assess how surfactants such as Polysorbate 80 may affect the stability of the protein.
Each of the two screenings included various analytical tests, as defined above and referred to below, on a variety of formulations subjected to varying degrees of heat load, mechanical load, and light load over a longer period of time (e.g., 1 month ). These FormulaDK 201800071 Y4 ring screenings made it possible to gather a considerable amount of date, which provided surprising and valuable insights that allow the development of new advantageous form ulations.
The results of the two formulation screenings are presented below.
Screening Experiment 1 - Analysis and Screening of Formulations of Example 1 Compared to Comparative Formulations of Example 3
The preliminary DoE screening (Step 1) estimated the effect that ionic strength (given by NaCl), pH, and various stabilizers exert on the protein over 10 short-term stability studies.
A statistical response surface-D-Optimal design was used. Three factors are taken into account:
Ion strength (driven by the NaCl concentration, which varied in the range of 25 mM-100 mM and set as a numerical factor);
- pH (range 4.6-6.4) buffered by histidine was investigated;
stabilizer / excipient (category factor comprising multiple levels: lysine hydrochloride, arginine + aspartic acid, mannitol, trehalose dihydrate).
These formulations were prepared as described in Example 1 above, starting from DS without Polysorbate 80 and were therefore free of surfactants.
Table 7 below summarizes the formulations tested in this screening. In addition to the proposed 8 formulations, two controls have also been analyzed for comparison:
• Commercial Humira drug product DP (formulated as i
Example 3 above) • MS drug DS DS formulated as commercial Humira-DP (formulated as in Example 3 above).
Table 7: List of DoE1 formulations (Step 1) screened under heat stress conditions (stability at 40 ° C) and high-speed determination of orotein30 unfolding temperature (DSF).
Form it Salt (NaCl) wife (mM) Buffer type (10 mM) pH stabilizer 18 25 histidine 6.0 Trehalose dihydrate (200 mM) 19 50 histidine 6.0 Lysine hydrochloride (100 mM) 20 100 histidine 6.0 Mannitol (200 mM) 21 50 histidine 6.2 Lysine hydrochloride (100 mM) 22 50 histidine 6.2 Arginine monohydrochloride + aspartic acid (80 mM + 20 mM) 23 75 histidine 6.2 Trehalose dihydrate (200 mM)
DK 201800071 Y4
24 25 histidine 6.4 Mannitol (200 mM) 25 100 histidine 6.4 Trehalose dihydrate (200 mM) Ref-1 (MS) Humira composition (formulation prepared with MS drug substance) - Example 3 Ref-2 (RMPUS) Commercial Humira-DP (USA) - Example 3 Ref-3 (RMP EU) Commercial Humira DP (EU) - Example 3
The formulations were investigated according to the plan presented in Table 8. Heat stress up to 1 month at 40 ° C is taken into account. High-speed assessment by DSF technique (which aims at rapid screening based on determination of the protein unfolding temperature) was performed at TO.
Table 8: Overview of analytical tests performed on preliminary DoE formulations (Step 1): 1 month heat load at 40 ° C.
Accelerated (40 ° C) Stability time (weeks) methods test 0 2u 4u OD Contents X - X SE-HPLC Attachment X X X Bioanalyzer purity X X X pH pH X X X osmolality osmolality X - - DSF Unfolding T X - -
1.1 Osmolality Screening
The osmolality of the total DoE1 fortunes starting with buffer exchange DS materials (Section 5.1.1) is presented in Table 9.
Most formulations were found to be in the osmolality range of 250-400 mOsm / kg, while slightly higher values were seen at the highest sodium chloride concentrations.
DK 201800071 Y4
Table 9: Osmolality (mOsm / kg) recorded at time 0 for DoE1 screening formulations
Form # Salt (NaCl) concentration (mM) Buffer type (10 mM) PH stabilizer Tido 18 25 histidine 6.0 Trehalose dihydrate (200 mM) 0324 19 50 histidine 6.0 Lysine hydrochloride (100 mM) 0317 20 100 histidine 6.0 Mannitol (200 mM) 0458 21 50 histidine 6.2 Lysine hydrochloride (100 mM) 0317 22 50 histidine 6.2 Arginine honohydrochloride + aspartic acid (80 mM + 20 mM) 0307 23 75 histidine 6.2 Trehalose dihydrate (200 mM) 0434 24 25 histidine 6.4 Mannitol (200 mM) 0307 25 100 histidine 6.4 Trehalose dihydrate (200 mM) 0496 Reference In-House (Humira composition, Merck Serono DS) 0374 RMP (USA) Humira REACH RMP (EU) Humira 0310
1.2 Protein content (OD)
The protein content of DoE1 formulations was determined at time 0 and after 1 month at 40 ° C.
FIG. Figure 1 is a bar graph showing the protein content (mg / ml) of the DoE1 formulations (from Example 1), together with reference standards (representing HUMIRA® comparison formulations), at an arbitrary starting point (blue bars, time = 0) and after 4 weeks ( red bars) of the formulation (s) heated to 40 ° C.
The results shown in Figs. 1 showed no occurrence of significant changes over time. All concentrations were found to be in line with the target value of 50 mg / ml.
1.3 Aggregation (SE-HPLC)
FIG. 2 is a bar graph showing% accumulation / aggregation as determined by SE-HPLC of DoE1 fortunes (from Example 1) along with standard references (representing HUMIRA® comparison formulations for an arbitrary start time (blue bars, time = 0) and both 2 weeks (green bars) and 4 weeks (orange bars) after the formulations have been heated to 40 ° C. The total amount of aggregates observed by SE-HPLC against the stability at 40 ° C is graphically depicted in Fig. 2. Minimal increases in aggregation 201800071 Y4 gene / accumulation in all formulations, however, all aggregation levels themselves after 1 month amounted to less than 1%.
1.4 Fragmentation (Bioanalyzer)
FIG. 3 is a bar graph showing% fragmentation as determined by a 5 Bioanalyzer, of the DoE1 formulations (from Example 1) together with standard references (representing HUMIRA® comparison formulations) for an arbitrary start time (dark blue bars, time = 0) and both 2 weeks (pink bars) and 4 weeks (pale blue bars) after the formulations have been heated to 40 ° C.
In FIG. 3 shows the variation of fragments over time as determined by Bioanalysts. Formulations at lower pHs tend to have higher fragmentation rates. In addition, the presence of amino acids in this pH range may aggravate the stability profile.
At pH> 6.0 and in the presence of sugar / polyalcohols, all the formulations, including the references, are comparable (fragmentation below 1% after 1 gauge down to 40 ° C.
As shown in Table 10, no deviations from the intended pH value were seen.
Table 10: pH value of DoE1 screening formulations determined relative to stability at 40 ° C
Stability time Form # Salt (NaCl) wife (mM) Buffer type (10 mM) pH stabilizer Tido 2weeks 40 ° C 4 weeks 40 ° C 18 25 histidine 6.0 Trehalose dihydrate (200 mM) 6.0 5.9 6.0 19 50 histidine 6.0 Lysine hydrochloride (100 mM) 6.0 6.0 6.0 20 100 histidine 6.0 Mannitol (200 mM) 6.0 6.0 6.0 21 50 histidine 6.2 Lysine hydrochloride (100 mM) 6.2 6.2 6.2 22 50 histidine 6.2 Arginine monohydrocloride + aspartic acid (80 mM + 20 mM) 6.2 6.2 6.2 23 75 histidine 6.2 Trehalose dihydrate (200 mM) 6.3 6.2 6.2 24 25 histidine 6.4 Mannitol (200 mM) 6.4 6.4 6.4 25 100 histidine 6.4 Trehalose dihydrate (200 mM) 6.4 6.4 6.4 Reference In-House (Humira composition, Merck Serono DS) 5.2 5.2 5.2 RMP (USA) Humira 5.3 5.3 5.3 RMP (EU) Humira 5.3 5.3 5.3
DK 201800071 Y4
1.6 Unfolding temperature (DSF)
DSF is a high-speed method aimed at determining protein unfolding temperature by increasing interactions with fluorescent probes as the temperature of the samples increases. As the protein begins to unfold, it will increasingly expose hydrophobic portions to the solvent, attracting the fluorescent probes that will transition from the free state in the solution (non-fluorescent) to the bound state (via hydrophobic interactions) with the protein, thereby amplifying the fluorescence signal.
From the assessment of the fluorescence signal, it was possible to determine the midpoint of the sigmoidal curves indicating the transition point of each formulation. It is assumed that the higher the transition point, the higher the resistance of the formulation to heat load.
The results of the assessment made on the DoE1 screening formulations are presented in Figs. 4. FIG. 4 is a bar graph showing the unfolding temperature (° C) as determined by the DSF of the DoE1 formulations (from Example 1) together with standard references (representing HUMIRA® comparative formulations).
The unfolding temperature of the three reference formulations is 71-72 ° C. Few formulations, other than the references, were found to have unfolding temperatures higher than 70 ° C, but those that did include:
Formulations 23, 24 and 25 (formulations in histidine buffer, pH 6.26.4, in the presence of either trehalose dihydrate or D-mannitol at varying sodium chloride concentrations).
Therefore, this test confirmed the results obtained previously for Bioanalyzer fragmentation: polyalcohols / sugars can positively affect the protein's heat stability, especially at pH> 6.2, while sodium chloride does not appear to significantly affect its performance.
1.7 Isoform Profile Change vs. RMP
The isoform profile of the DoE Screening Formulation 25 has been examined after 10-11 weeks at 40 ° C and compared with reference samples.
Data with respect to main peak and cluster clusters are given in Table 11.
Comparable variations are obtained for the four tested samples with slightly better results for Formulation 25 (in histidine).
DK 201800071 Y4
Table 11: Isoform profile at iCE280 for the most promising formulations from DoE screening 1 and references
peak
ID Time 0 10 weeks (40 ° C) 11 weeks (40 ° C) DoEI-25 56.5 - 42.2 Ref-1 (MS) 55.8 38.5 - Ref-3 RMP (EU) 56.5 40.7 - Ref-2 RMP (US) 56.8 40.6 -
Sur cluster
ID Time 0 10 weeks (40 ° C) 11 weeks (40 ° C) DoEI-25 19.5 - 36.9 Ref-1 (MS) 19.8 40.5 - Ref-3 RMP (EU) 19.5 38.9 - Ref-2 RMP (US) 20.2 39.8 -
Conclusion of Screening Experiment 1
The results obtained from the Bioanalyzer and DSF tests are combined using the response surface ANOVA model to determine the best compositions that could possibly guarantee the highest thermal stability of the protein.
The list of recommended compositions is presented in Table 12, which also compares10 the results for the obtained prototype formulations with Humira-RMP with respect to unfolding temperature and fragmentation change over 1 month at 40 ° C.
Formulation C corresponds to DoE1 Formulation 25 and real data is reproduced.
By comparing these formulations with RMP, it can be concluded that the behavior of these prototype formulations in response to heat load is comparable to that seen for RMP.
Table 12: Results of EoE1 experiments: recommended compositions for second screening
Form Salt (NaCl) mM Buffer type (10 mM) pH stabilizer C 100 histidine 6.4 Trehalose dihydrate (200 mM)
DK 201800071 Y4
Somewhat unexpectedly, formulations containing trehalose dihydrate as the sole stabilizer performed very well, especially with regard to fragmentation inhibition, unfolding inhibition and pH maintenance. Such trehalose-based formulations also performed well in aggregation / accumulation and precipitation. Trehalose being such a strong stabilizer candidate, especially alone, was highly promising in view of its antioxidant properties, which will impart additional long-term chemical stability (especially to oxidation and / or photooxidation) to adalimumab formulations. Furthermore, it was considered particularly encouraging that trehalose can be used alone and yet still perform excellently, and it paves the way for less complex formulations that use fewer ingredients, which in turn will reduce the processing and costs associated with producing the relevant adalimum drug product. . As such, these trehalose-based formulations were passed on to another round of screening experiments to fine-tune the formulations.
Screening Experiment 2 - Analysis and Screening of Formulations of Example 2 versus Comparative Formulations of Example 3
A formulation prototype from the previous screening was determined (Table 12). Since the previous step was performed without added surfactant, the second step aimed to screen a total range of levels of surfactant in the form of Polysorbate 80 (range: 0-1 mg / ml) to assess whether surfactant addition is necessary to promote protein stability.
Table 3 (Example 2) summarizes the design of this second step of the study and lists the formulations (DoE2 formulations) investigated in this second screening round.
Typically, surfactants have been observed to contrast with accumulation / aggregation induced by mechanical stress, and shake-load studies have therefore been conducted to assess how Polysorbate 80 affects protein stability and the reaction to shaking.
As for step 1, the reference compositions described in Example 3 have also been evaluated to provide an assessment basis for the development of a new formulation.
The complete list of analyzes performed on this group of formulations is presented in Table 13. In this second screening, the respective formulationsDK 201800071 Y4 are subjected to three different types of load, namely heat load, mechanical load and light load.
Table 13: Summary of analytical tests performed on DoE2 formulations (Step 2): 1 month heat load conditions at 40 ° C (A), shake load at 5,200 rpm (B) and light exposure according to ICH Q1 8 (C)
Heat load at 40 ° C
Forced (40 ° C) Stability time (weeks) methods test 0 2u 4u OD Contents X - x iCE280 isoforms x x x SE-HPLC Attachment x x x Bionalyzer purity x x x PH pH x x x osmolality osmolality x - - nephelometry turbidity x x x DSF Unfolding T x - -
A. Shaking load conditions
Shake load (200 rpm) Stability time (hours) methods test 0 24 h 48 h OD Contents x - - SE-HPLC Attachment x x x Bioanalyzer purity x x x PH pH x x x nephelometry turbidity x x x
B. Light exposure, 7 hours exposure at 765W / m ² (ICH Q1B).
Light exposure Sample methods test Tido exposed OD Contents x - iCE280 isoforms x x SE-HPLC Attachment x x Bioanalyzer purity x x PH pH x x nephelometry turbidity x x
DK 201800071 Y4
Heat load studies were performed by simply heating a sample of the relevant formulations at the set temperature for the stipulated period (typically 2 weeks or 4 weeks / month).
Mechanical load studies were performed by simply shaking a sample of the relevant room temperature formulations at 200 rpm for the stipulated period (typically 24 hours or 48 hours).
Light exposure studies were performed by simply exposing a sample of the relevant formulations to 765 W / m ² light (in accordance with the European Medicines Agency's ICH Q1 B Guidelines on Photostability Testing of New Active Substances and Medical Products) for 7 hours.
2.1 Osmolality
The osmolality of the DoE2 screening formulations is presented in Table 14. The values, in the range of 378-401 mOsm / kg, are probably overestimated due to the presence of trehalose dihydrate which may lead to some increase in viscosity, which affects the cryoscopic point of the solutions and thus the osmolality. This was confirmed by measurements for other test formulations, which were diluted 3 times with WFI prior to the osmolality test to lower the viscosity: the true osmolality for all these formulations is <350 mOsm / kg.
Table 14: Osmolality of DoE2 Screening Formations (Investigated Undiluted)
Form # Salt (NaCl) concentration (mM) Buffer type (10 mM) PH stabilizer Surfactant (Polysorbate 80) concentration (mg / ml) Tido DoE2-7 50 histidine 6.4 Trehalose dihydrate (200 mM) 0 381 DoE2-8 50 histidine 6.4 Trehalose dihydrate (200 mM) 0.5 381 DoE2-9 50 histidine 6.4 Trehalose dihydrate (200 mM) 1 378
2.2 Protein content
The protein content of all DoE2 formulations at time 0 was in line with the protein concentration target of 50 mg / ml (Table 15).
Table 15: Protein content (OD) of DoE2 screening formulations (investigated undesired)
DK 201800071 Y4
Form # Salt (NaCl) concentration (mM) Buffer type (10 mM) PH stabilizer Surfactant (Polysorbate 80) concentration (mg / ml) Time 0 DoE2-7 50 histidine 6.4 Trehalose dihydrate (200 mM) 0 49.9 DoE2-8 50 histidine 6.4 Trehalose dihydrate (200 mM) 0.5 50.2 DoE2-9 50 histidine 6.4 Trehalose dihydrate (200 mM) 1 50.4
2.3 Heat Load Units (SE-HPLC)
The variations in the total amount of aggregates by SE-HPLC are presented in Figs. 5. FIG. Figure 5 is a bar graph showing% aggregation, as determined by SE-HPLC, of the DoE2 formulations (from Example 2) together with standard references (representing HUMIRA® comparison formulations) at an arbitrary starting point (red bars, time = 0) and after both 2 weeks (green bars) and 4 weeks (purple bars) for formulations heated to 40 ° C.
Minimal changes were seen in all formulations, with the total amount of aggregates after 1 month at 40 ° C being below 1%.
The DoE1 screening formulations did just as well as the RMP materials or slightly better.
2.4 Fragmentation with Heat Load (Bioanalyzer)
The variations in fragments with Bioanalyzer are shown in Figs. 6. Figure 6 is a bar graph showing% fragmentation, as determined with a Bioanalyzer, of the DoE2 formulations (from Example 2) along with standard references (representing HUMIRA® comparison formulations) at an arbitrary starting point (blue bars, time = 0) and after both 2 weeks (red bars) and 4 weeks (green bars) for formulations heated to 40 ° C.
Formulation DoE2-7 (no Polysorbate 80) undergoes a consistent increase in fragments, while the other two, in the presence of surfactant, were found to be comparable to the RMP materials. Considering data available from the DoE1 experiments on Formulation # 25 (comparable to Formulation 7 in DoE2), it can be concluded that the increased degradation of DoE2-7 can be attributed to a possible contamination of the sample.
2.5 Isoform profile with heat load (ICE280)
The changes with respect to the main peak and acid cluster for the three formulations over 1 month at 40 ° C are shown in Figs. 7 and 8.
Figure 7 is a bar graph showing the main top isoform profile, as determined by iCE280 analysis, of the DoE2 formulations (from Example 2) at an arbitrary starting point (blue bars, time = 0) and after both 2 weeks (red bars) and 4 weeks
DK 201800071 Y4 (green bars) for formulations heated to 40 ° C.
Figure 8 is a bar graph showing the cluster cluster topoform profile, as determined by iCE280 analysis, of the DoE2 formulations (from Example 2) at an arbitrary starting point (blue bars, time = 0) and after both 2 weeks (red bars) and 4 weeks (green bars) for formulations heated to 40 ° C.
The major changes are seen in DoE2 - 7 (-15% in the main peak), but this may result from a possible contamination of the sample as highlighted above.
These results confirm the experimental evidence already highlighted by icE280 on the prototype formulations (as a result of initial screening): formulations in histidine show comparable degradation rates in isoform profile relative to RMP.
The results for acid cluster are in line with the top observations made.
2.6 pH screening with heat load
The variation in pH of the DoE2 formulations (from Example 2) over a period of time during which the formulations are heated to 40 ° C is shown in Table 1 6.
pH decrease was seen in DoE2-7, as shown in Table 16. This may be due to possible contamination / bacterial propagation in the samples.
Table 16: DoE2 screening: pH (heat load at 40 ° C)
Form # Salt (NaCl) concentration (mM) Buffer type (10 mM) PH stabilizer Surfactant (Polysorbate 80) concentration (mg / ml) Tido 2 weeks (40 ° C) 4 weeks (40 ° C) DoE2-7 50 histidine 6.4 Trehalose dihydrate (200 mM) 0 6.4 4.3 4.3 DoE2-8 50 histidine 6.4 Trehalose dihydrate (200 mM) 0.5 6.4 6.4 6.4 DoE2-9 50 histidine 6.4 Trehalose dihydrate (200 mM) 1 6.4 6.4 6.4
2.7 Turbidity with heat load (nephelometry)
FIG. 9 is a bar graph showing the turbidity, as determined by nephelometry, of the DoE2 formulations (from Example 2) at an arbitrary starting point (blue bars, time = 0) and after both 2 weeks (red bars) and 4 weeks (green bars) ) for formulations heated to 40 ° C.
The turbidity of the three solutions is currently 0 in the range of typical opalescent solutions (6-18 NTU). In terms of time, the original DS materials with typical turbidity of 19-52 NTU, the DP solutions after aseptic filtration are considerably clear.
It should be noted that the turbidity value for Humira RMP is usually around
DK 201800071 Y4
NTU, in line with our formulations.
2.8 Mechanical load units (SE-HPLC)
Figure 10 is a bar graph showing% accumulation / aggregation, as determined by SE-HPLC, of the DoE2 formulations (from Example 2) at an arbitrary starting point (blue bars, time = 0) and after both 24 hours (red bars) and 48 hours (green bars) for mechanically moving formulations (shaking).
The variation in the total amount of aggregates calculated by SE-HPLC is shown in Figs. 10. Minimal changes (+ 0.1%) were observed for all histidine buffer formulations.
2.9 Fragmentation with mechanical loading (Bioanalyzer)
FIG. Figure 11 is a bar chart showing% fragmentation, as determined with a Bioanalyzer, of the DoE2 formulations (from Example 2) at an arbitrary starting point (blue bars, time = 0) and after both 24 hours (red bars) and 48 hours ( green bars) for mechanically moving formulations (shaking).
The variations in fragments when calculated with Bioanalyzer are presented in Figs. 11. Minimal changes are seen as all recorded values are equal to or below 0.5%.
After 48 hours shaking at room temperature, all samples showed fragmentation between 0.2 and 0.4%. No tendency was observed for increasing fragmentation after mechanical shaking.
2.10 pH screening with mechanical loading
The variation in pH of the DoE2 formulations (from Example 2) over a period of time during which the formulations are mechanically moved (shaking) is shown in Table 17. No changes were seen.
Table 17: DoE2 screening: pH (mechanical shaking)
Form # Salt (NaCl) concentration (mM) Buffer type (10 mM) PH stabilizer Surfactant (Polysorbate 80) concentration (mg / mL) Tido 24 hours 48 hours DoE2-7 50 histidine 6.4 Trehalose dihydrate (200 mM) 0 6.4 6.5 6.5 DoE2-8 50 histidine 6.4 Trehalose dihydrate (200 mM) 0.5 6.4 6.4 6.4 DoE2-9 50 histidine 6.4 Trehalose dihydrate (200 mM) 1 6.4 6.4 6.4
2.11 Turbidity with mechanical load (nephelometry)
Figure 12 is a bar graph showing% turbidity, as determined by nephelometry, of the DoE2 formulations (from Example 2) at an arbitrary starting point (blue bars, time = 0) and after both 24 hours (red bars) and 48 hours ( green columnDK 201800071 Y4 clay) for mechanically moving formulations (shaking). No changes were observed.
2.12 Light Load Aggregates (SE-HPLC)
Figure 13 is a bar graph depicting% accumulation / aggregation, as determined by SE-HPLC, of the DoE2 formulations (from Example 2) along with standard references (representing HUMI RA® - similar form of study) before exposure to light (blue bars, time = 0) and after 7 hours of light exposure at 765 W / m ² (red bars).
Comparisons were also made with Humira samples (from the US and the EU) subject to the same conditions. In the RMP, the aggregation increases up to 9-15% after light exposure (at time 0 the aggregate amount is below 1%). All DoE2 formulations show less or comparable increases and thus better / comparable heat resistance. In greater detail:
• Formulations in histidine buffer: 5.8 -> 9.2% total amount of aggregates after light exposure.
2.13 Fragmentation with Frost Load (Bioanalvzer)
Figure 14 is a bar graph showing% fragmentation, as determined with a Bioanalyzer, of the DoE2 formulations (from Example 2) before exposure to light (blue bars, time = 0) and after 7 hours of light exposure at 765 W / m ² ( red bars).
Minimal increases were noted (maximum + 0.3% after exposure). All fragments are well below 1% after 7 hours of exposure (Fig. 14).
2.14 Isoform Profile with Frost Load (ICE2280)
Figure 15 is a bar graph showing the main top isoform profile, as determined by iCE280 analysis, of the DoE2 formulations (from Example 2) together with standard references (representing HUMIRA® comparison formulations) before exposure to light (blue bars, time = 0) and after 7 hours of light exposure at 765 W / m ² (red bars).
Figure 16 is a bar graph showing the cluster cluster topo isoform profile, as determined by iCE280 analysis, of the DoE2 formulations (from Example 2) together with standard references (representing HUMIRA® comparison formulations) before exposure to light (blue bars, time = 0) and after 7 hours of light exposure at 765 W / m ² (red bars).
In Humira-RMP, light exposure produces significant effects: most notably, decreases in head peak frequency (approximately -9%) and concomitant increase in acidic cluster (up to +15%) associated with photo-oxidation phenomena.
Formulations in histidine were found to be more prone to degradation
Due to light exposure than the RMP: the decrease in head peak frequency is -11.4% (DoE2 -7) or even more (about -18% for others), increases in acid cluster went up to + 27%.
Histidine is subject to oxidation caused by both extensive light exposure and degradation products (typically peroxides) released by polysorbates under stressful conditions. Therefore, polysorbate 80+ histidine is a combination that can create increased instability under light exposure.
To better elucidate the effect of surfactant and determine whether it is required to prevent protein degradation / particle formation after freeze-thaw cycles, targeted experiments were performed which showed that Polysorbate does not produce any additional effect. This could eventually lead to a histidine-free surfactant formulation.
2.15 Turbidity with Ivy Load (Nephelometry).
Figure 17 is a bar graph showing the turbidity, as determined by nephelometry, of the DoE2 formulations (from Example 2) before exposure to light (blue bars, time = 0) and after 7 hours of light exposure at 765 W / m ² (red bars). There were virtually no changes.
2.16 oH screening with Ivy load
The variation in pH in the DoE2 formulations (from Example 2) over a period of time during which the formulations are exposed for 7 hours to light at 765 W / m ² is shown in Table 18. No changes were seen.
Table 18: DoE2 screening: pH (light exposure)
Form # Salt (NaCl) concentration (mM) Buffer type (10 mM) PH stabilizer Surfactant (Polysorbate 80) concentration (mg / ml) Tido After exposure DoE2-7 50 histidine 6.4 Trehalose dihydrate (200 mM) 0 6.4 6.5 DoE2-8 50 histidine 6.4 Trehalose dihydrate (200 mM) 0.5 6.4 6.5 DoE2-9 50 histidine 6.4 Trehalose dihydrate (200 mM) 1 6.4 6.5
2.17 Effect of surfactant on freeze-thaw cells
Isoform profiles, aggregates and invisible particles for the three DoE2 formulations have been determined before and after five freeze-thaw cycles (-80 ° C-> room temperature) to evaluate whether the surfactant exerts any effect.
Figure 18 is a bar graph showing the main top isoform profile, as determined by iCE280 analysis, of the DoE2 formulations (from Example 2) before (blue
DK 201800071 Y4 columns, time = 0) and after (red bars) five freeze-thaw cycles (-80 ° C -> room temperature).
Figure 19 is a bar graph showing the cluster cluster topoform profile, as determined by iCE280 analysis, of the DoE2 formulations (from Example 2) before (blue bars, time = 0) and after (red bars) five freeze thaw cycles (-80 ° C -> room temperature).
Figure 20 is a bar graph showing% accumulation, as determined by SEHPLC, of the DoE2 formulations (from Example 2) along with standard references (representing HUMIRA® comparison formulations) before (blue bars, time = 0) and after (red bars) five freeze-thaw cycles (-80 ° C -> room temperature).
Figure 21 is a bar graph showing the number concentration (# / mg) of invisible particles having a particle size below or equal to 10 micrometers, as determined by count analysis of invisible particles, of the DoE2 formulations (from Example 2) before (blue bars) , time = 0) and after (red bars) five freeze-thaw cycles (-80 ° C -> room temperature).
Figure 22 is a bar graph showing the number concentration (# / mg) of invisible particles having a particle size below or equal to 25 micrometers, as determined by count analysis of invisible particles, of the DoE2 formulations (from Example 2) before (blue bars) , time = 0) and after (red bars) five freeze-thaw cycles (-80 ° C -> room temperature).
No changes in isotherms and aggregates (Figs. 18-20) were observed after freeze-thaw cycles, while minimal, noncritical changes (Figs. 21-22) in non-visible particles were noted and found not to be associated with the presence of surfactant. fabric. A greater number of particles detected in DoE2-8 are most likely due to the method of preparation of the sample.
Therefore, nothing is gained by adding a surfactant for the purpose of preventing particle and aggregate / protein degradation during the freeze-thaw cycles. This underlines the effectiveness of the new formulations independently of surfactant.
Conclusion of Screening Experiment 2
On the basis of the data collected relevant to heat load, mechanical load and light load, the following conclusion can be drawn:
Formulations in 10 mM histidine buffer at pH 6.4 (DoE2 -7, DoE2 - 8, DoE2 - 9):
At heat load, a performance similar to Humira was found;
DK 201800071 Y4
Minimal increase of aggregation after mechanical shaking;
Increased degradation and isoform profile change with Humira due to histidine sensitivity to light and degradation products from Polysorbate 80. The formulation without Polysorbate 80 in this group (DoE2 - 7) is still slightly inferior to RMP but far superior to the other histidine + Polysorbate. 80 (0.5 or 1.0 mg / ml).
The presence of Polysorbate 80 has been calculated to assess its effectiveness and function as a protein protector (protection against freeze-thaw cycles). After 5 freeze-thaw cycles (-80 ° C -> room temperature) it was seen that the surfactant did not produce any extra effect and the recommendation is to proceed with DoE2 - 7, which is free of surfactant (50 mg / 200 mM trehalose dihydrate, 50 mM sodium chloride in 10 mM histidine, pH 6.4).
Based on the screening work carried out on various formulations varying in buffer / pH, stabilizer, amount of isotonicity agent (NaCl) and surfactant content (Polysorbate 80), the best composition shows comparable or even improved properties in relation to to Humira under various load conditions (heat load, mechanical load, light) have been identified as:
[0001]
Ingredient Amount (mg / ml) adalimumab 50 Histidine (anhydrous) 1.55 * trehalose dihydrate 75.67 ** Sodium chloride 2.92 *** WFI and sodium hydroxide q.b. for adjusting the pH to6.4
* corresponding to 10 mM histidine; ** equivalent to 200 mM; *** equivalent to 50 mM
Such formulations can easily be incorporated into pre-filled glass syringes with 29G ^1/2 ”needles.
DK 201800071 Y4
ABBREVIATIONS
Die Experimental Design DP Pharmaceutical Product DS drug Substance DSF Dif f is a t i elscan n i ngf lu or i met ri OD Optical density PES polyethersulfone rPM RPM RT room temperature SE-HPLC High performance size exclusion liquid chromatography SMI Summary Manufacturing Instructions SOP Standard Operating Procedure WI Wiring harness
DK 201800071 Y4
Further Embodiments:
Further aspects and embodiments of the production are reproduced in the numbered sections below:
A liquid pharmaceutical composition comprising:
(a) adalimumab;
(b) a histidine buffer agent (or histidine buffer system); and (c) a sugar stabilizer;
wherein the composition has a pH greater than or equal to 6.30.
2. Liquid pharmaceutical composition as described in Section 1, wherein the composition has a pH between 6.3 and 6.5.
3. Liquid pharmaceutical composition as described in any preceding section wherein the sugar stabilizer is trehalose.
A liquid pharmaceutical composition as described in any preceding section, wherein the composition is either (substantially or completely) free of amino acids other than histidine or comprises one or more amino acids other than histidine at a (total) concentration of no more than 0. , 1 mM.
5. Liquid pharmaceutical composition as described in section 4, wherein the composition is free of amino acids other than histidine.
A liquid pharmaceutical composition as described in any preceding section, wherein the composition is either (substantially or completely) free of surfactants or comprises one or more surfactants at a (total) concentration not exceeding 0.001 Μ.
A liquid pharmaceutical composition as described in any preceding section, wherein the composition is either (substantially or completely) free of arginine (preferably L-arginine) or comprises arginine at a concentration not exceeding 0.1 mM.
A liquid pharmaceutical composition as described in any preceding section, wherein the composition is either (substantially or completely) free of phosphate buffer idles or comprises a phosphate buffer system at a concentration not exceeding 0.1 mM.
A liquid pharmaceutical composition as described in any preceding paragraph, comprising a tonizing agent selected from sodium chloride, potassium chloride, magnesium chloride or calcium chloride.
A liquid pharmaceutical composition as described in any preceding section wherein the osmolality of the composition is
DK 201800071 Y4 between 220 and 390 mOsm / kg.
A liquid pharmaceutical composition as described in any preceding section, wherein the protein unfolding temperature of adalimumab in the liquid pharmaceutical composition is greater than or equal to 70 ° C.
A liquid pharmaceutical composition as described in any preceding section, wherein the composition comprises adalimumab, histidine (or histidine buffer substances) and trehalose in a weight ratio of 2575: 0.31-7.8: 15-140, respectively.
A liquid pharmaceutical composition as described in any preceding section, wherein the composition comprises adalimumab, histidine (or histidine buffer substances), trehalose and sodium chloride in a weight ratio of 45-55: 0.77-2.2: 65-72: 2 , 7-3.1, respectively.
A liquid pharmaceutical composition as described in any preceding section, wherein the composition comprises:
to about 55 mg / ml adalimumab;
to 14 mM histidine (or histidine buffer system);
190 to 210 mM trehalose;
to 60 mM sodium chloride;
water (of injection purity);
wherein the composition:
o has a pH between 6.3 and 6.5;
o is free of arginine or comprises arginine at a concentration not exceeding 0.001 mM;
o is free of amino acids other than histidine or comprises one or more amino acids other than histidine at a (total) concentration not exceeding 0.001 mM;
o is free of surfactants or comprises one or more surfactants at a (total) concentration not exceeding 0.0001 mM; and / or o is free of phosphate buffer agents (e.g., sodium dihydrogen phosphate, disodium hydrogen phosphate) or comprises a phosphate buffer system at a concentration not exceeding 0.001 mM.
A drug dispensing device comprising a liquid pharmaceutical composition as described in any of the preceding sections.
16. Liquid pharmaceutical composition as described in any of sections 1 to 14 for use in the treatment of rheumatoid
DK 201800071 Y4 arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and / or juvenile idiopathic arthritis.
DK 201800071 Y4

权利要求:
Claims (13)
[1]
UTILITY MODEL REQUIREMENTS
An aqueous pharmaceutical composition comprising:
(a) adalimumab;
(b) histidine buffer agent or histidine buffer system;
(c) sugar stabilizer selected from the group including trehalose, sucrose, mannitol, sorbitol, maltose, lactose, xylitol, arabitol, erythritol, lactitol, maltitol, inositol; eg (d) polysorbate 20;
wherein the composition:
Is either free of amino acids other than histidine or comprises one or more amino acids other than histidine at a total concentration not exceeding 0.1 mM; and • is either free of phosphate buffer agents or comprises a phosphate buffer system at a concentration not exceeding 0.1 mM;
wherein the composition further comprises a citrate buffer and wherein the composition comprises the sugar stabilizer at a concentration of 50 to 400 mM.
[2]
The aqueous pharmaceutical composition of claim 1, wherein the composition has a pH of between 5.0 and 6.7.
[3]
An aqueous pharmaceutical composition according to any one of the preceding claims, wherein the composition comprises adalimumab at a concentration of 25 mg / ml to 75 mg / ml.
[4]
An aqueous pharmaceutical composition according to any one of the preceding claims, wherein the composition comprises the histidine buffer agent or histidine buffer system at a concentration of 2 to 50 mM.
[5]
An aqueous pharmaceutical composition according to any one of the preceding claims, wherein the composition comprises polysorbate 20 at a concentration of 0.05 to 2 mg / ml.
[6]
An aqueous pharmaceutical composition according to any one of the preceding claims, wherein the composition comprises polysorbate 20 at a concentration of 0.9 to 1.5 mg / ml.
[7]
An aqueous pharmaceutical composition according to any one of the preceding claims, wherein the sugar stabilizer is a sugar alcohol selected from the group consisting of sorbitol, xylitol, arabitol, erythritol, lactitol, maltitol and inositol.
[8]
An aqueous pharmaceutical composition according to any one of the preceding claims, wherein the sugar stabilizer is sorbitol.
DK 201800071 Y4
[9]
An aqueous pharmaceutical composition according to any one of the preceding claims, wherein sodium chloride is present at a concentration of between 25 and 100 mM if the composition comprises sodium chloride as an optional tonicity agent.
[10]
An aqueous pharmaceutical composition according to any one of the preceding claims, wherein the composition comprises:
(a) 45 to 55 mg / ml adalimumab;
(b) 2 to 50 mM histidine buffer agent or histidine buffer system;
(c) 50 to 300 mM sorbitol; and (d) 0.05 to 2 mg / ml polysorbate 20;
wherein the composition:
Is either free of amino acids other than histidine or comprises one or more amino acids other than histidine at a total concentration not exceeding 0.1 mM; and • are either free of phosphate buffer agents or comprise a phosphate buffer system at a concentration not exceeding 0.1 mM.
[11]
An aqueous pharmaceutical composition according to any one of the preceding claims, wherein the composition comprises:
(a) 45 to 55 mg / ml adalimumab;
(b) 2 to 50 mM histidine buffer agent or histidine buffer system;
(c) 50 to 300 mM sorbitol; and (d) 0.9 to 1.5 mg / ml polysorbate 20;
wherein the composition:
• has a pH of between 5.0 and 6.7;
• is free of amino acids other than histidine; and • is free of phosphate buffer agents.
[12]
A drug dispensing device comprising an aqueous pharmaceutical composition according to any one of the preceding claims.
[13]
An aqueous pharmaceutical composition according to any one of claims 1 to 11 for use in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and / or juvenile idiopathic arthritis.
DK 201800071 Y4
Protein content (rag / mL)

£ 3 Time 0 to 2 weeks 40 T '□ 4 Ttger 407:

DK 201800071 Y4
Time O □ 2 weeks 4 (ΗΖΠ 4 weeks 404)
Unfolding temperature (° C) Fragments (%)


DK 201800071 Y4
Aggregates (%)

Fs / »% lo. 5

Fs / 4 r »lO. ISLAND
DK 201800071 Y4
Acid cluster (%) Main peak (%)



DK 201800071 Y4 total (%) Turbidity (NTU)

Π “ίΟ Π rib. y

类似技术:

---

公开号 | 公开日 | 专利标题

---

DK201800071Y4|2018-12-13|Liquid pharmaceutical composition

---

DK202000030Y3|2020-05-26|Liquid pharmaceutical composition

---

US20210196824A1|2021-07-01|Liquid pharmaceutical composition

---

AU2020201090B2|2022-03-10|Liquid pharmaceutical composition

同族专利:

---

公开号 | 公开日

---

JP2017516847A|2017-06-22|

---

DK201800071Y4|2018-12-13|

---

CY1120488T1|2019-07-10|

---

DK201800070Y8|2019-07-09|

---

AU2020201090A1|2020-03-05|

---

AU2015263246A1|2016-11-17|

---

AU2015263246B2|2018-06-21|

---

US10493152B2|2019-12-03|

---

HUE040097T2|2019-02-28|

---

US10772961B2|2020-09-15|

---

SI3148510T1|2018-10-30|

---

DK201800070Y4|2018-12-13|

---

EP2946766B1|2016-03-02|

---

IL249117D0|2017-01-31|

---

EP3659582A1|2020-06-03|

---

RS57772B1|2018-12-31|

---

DK201800070U1|2018-09-18|

---

EP3148510A1|2017-04-05|

---

DK3148510T3|2018-07-16|

---

LT3148510T|2018-10-10|

---

JP2022003091A|2022-01-11|

---

US20170189527A1|2017-07-06|

---

US20210023215A1|2021-01-28|

---

AU2018222887B2|2020-02-27|

---

CA2947487A1|2015-11-26|

---

EP2946766A1|2015-11-25|

---

ES2683194T3|2018-09-25|

---

JP6962984B2|2021-11-05|

---

CA2947487C|2019-09-24|

---

US20200085948A1|2020-03-19|

---

PL3148510T3|2018-11-30|

---

CN106659781A|2017-05-10|

---

PT3148510T|2018-09-28|

---

EP3148510B1|2018-06-27|

---

CA3050875A1|2015-11-26|

---

AU2018222887A1|2018-09-13|

---

ES2572919T3|2016-06-03|

---

HK1257026A1|2019-10-11|

---

JP2020033361A|2020-03-05|

---

CN108785670A|2018-11-13|

---

EP3403646A1|2018-11-21|

---

HRP20181226T1|2018-10-19|

---

WO2015177058A1|2015-11-26|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

JPS6388197A|1986-09-30|1988-04-19|Tosoh Corp|Stabilizing method for monoclonal antibody|

---

PL188192B1|1996-02-09|2004-12-31|Abbott Lab Bermuda Ltd|Human antibodies capable to bond human tnf alpha|

---

US5900404A|1997-08-15|1999-05-04|Amgen Inc.|Chemical modification of proteins to improve biocompatibility and bioactivity|

---

US20040033228A1|2002-08-16|2004-02-19|Hans-Juergen Krause|Formulation of human antibodies for treating TNF-alpha associated disorders|

---

PL2335725T3|2003-04-04|2017-04-28|Genentech, Inc.|High concentration antibody and protein formulations|

---

WO2005072772A1|2004-01-30|2005-08-11|Suomen Punainen Risti Veripalvelu|Pharmaceutical compositions|

---

CN101721701A|2004-07-23|2010-06-09|健泰科生物技术公司|Crystallization of antibodies or fragments thereof|

---

JO3000B1|2004-10-20|2016-09-05|Genentech Inc|Antibody Formulations.|

---

EP1858552A2|2005-03-08|2007-11-28|Pharmacia & Upjohn Company LLC|Composition comprising human igg2 antibody and a chelating agent|

---

MX2007015280A|2005-06-07|2008-04-08|Esbatech Ag|Stable and soluble antibodies inhibiting tnf??.|

---

SG186607A1|2007-11-30|2013-01-30|Abbott Lab|Protein formulations and methods of making same|

---

US8080518B2|2007-12-05|2011-12-20|Arbor Vita Corporation|Co-administration of an agent linked to an internalization peptide with an anti-inflammatory|

---

WO2010077422A2|2008-10-29|2010-07-08|Wyeth Llc|Formulations of single domain antigen binding molecules|

---

CA2742990A1|2008-11-17|2010-05-20|Genentech, Inc.|Method and formulation for reducing aggregation of a macromolecule under physiological conditions|

---

RU2560701C2|2009-05-04|2015-08-20|Эббви Байотекнолоджи Лтд.|Stable compositions with high concentrations of proteins of human antibodies against tnf-alpha|

---

EP3409289B1|2010-02-26|2020-09-30|Novo Nordisk A/S|Stable antibody containing compositions|

---

CN105521491B|2010-03-01|2020-03-24|西托戴恩有限公司|Concentrated protein formulations and uses thereof|

---

US20110223208A1|2010-03-09|2011-09-15|Beth Hill|Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations|

---

WO2011119487A2|2010-03-22|2011-09-29|Genentech, Inc.|Compositions and methods useful for stabilizing protein-containing formulations|

---

EP2399604A1|2010-06-25|2011-12-28|F. Hoffmann-La Roche AG|Novel antibody formulation|

---

PL2637690T3|2010-11-11|2017-03-31|Abbvie Biotechnology Ltd|HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS|

---

EP2471554A1|2010-12-28|2012-07-04|Hexal AG|Pharmaceutical formulation comprising a biopharmaceutical drug|

---

DK2726090T3|2011-07-01|2020-01-20|Biogen Ma Inc|ARGIN-FREE TNFR: FC-FUSION POLYPEPTIME COMPOSITIONS|

---

GB201112429D0|2011-07-19|2011-08-31|Glaxo Group Ltd|Antigen-binding proteins with increased FcRn binding|

---

KR101730694B1|2012-03-07|2017-04-27|카딜라 핼쓰캐어 리미티드|Pharmaceutical Formulations of TNF-Alpha Antibodies|

---

WO2013186230A1|2012-06-12|2013-12-19|Boehringer Ingelheim International Gmbh|Pharmaceutical formulation for a therapeutic antibody|

---

PE20191815A1|2012-09-07|2019-12-27|Coherus Biosciences Inc|STABLE AQUEOUS FORMULATIONS OF ADALIMUMAB|

---

CN104768578A|2012-10-25|2015-07-08|米迪缪尼有限公司|Stable, low viscosity antibody formulation|

---

EP2727602A1|2012-10-31|2014-05-07|Takeda GmbH|Method for preparation of a high concentration liquid formulation of an antibody|

---

JP6339578B2|2012-10-31|2018-06-06|タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ|Lyophilized preparation containing GM-CSF neutralizing compound|

---

AR093297A1|2012-10-31|2015-05-27|Amgen Res Gmbh|LIQUID FORMULATION THAT INCLUDES A GM-CSF NEUTRALIZING COMPOUND|

---

EP3466973A1|2012-11-01|2019-04-10|AbbVie Inc.|Stable dual variable domain immunoglobulin protein formulations|

---

CN104707146B|2013-12-16|2019-04-16|浙江海正药业股份有限公司|A kind of pharmaceutical composition containing adalimumab|

---

IN2014MU01248A|2014-04-02|2015-10-09|Intas Pharmaceuticals Ltd|

---

EP2946767B1|2014-05-23|2016-10-05|Ares Trading S.A.|Liquid pharmaceutical composition|

---

ES2572919T3|2014-05-23|2016-06-03|Ares Trading S.A.|Liquid pharmaceutical composition|

---

LT2946765T|2014-05-23|2016-11-25|Ares Trading S.A.|Liquid pharmaceutical composition|

---

CN109563161A|2016-02-03|2019-04-02|安口生物公司|For improving the buffer preparation of Antibody stability|EP2946767B1|2014-05-23|2016-10-05|Ares Trading S.A.|Liquid pharmaceutical composition|

---

ES2572919T3|2014-05-23|2016-06-03|Ares Trading S.A.|Liquid pharmaceutical composition|

---

LT2946765T|2014-05-23|2016-11-25|Ares Trading S.A.|Liquid pharmaceutical composition|

---

BR112020019861A2|2018-03-29|2021-01-05|Airway Therapeutics, Inc.|METHODS AND COMPOSITIONS THAT UNDERSTAND SURFACTANT PROTEIN D |

---

WO2020138517A1|2018-12-24|2020-07-02|삼성바이오에피스 주식회사|PHARMACOLOGICAL COMPOSITION COMPRISING ANTI-TNFα ANTIBODY|

---

EP3909607A1|2019-01-11|2021-11-17|Samsung Bioepis Co., Ltd.|Pharmaceutical composition comprising antibody, device comprising same, and use thereof|

法律状态:
2018-12-05| UAT| Utility model published|Effective date: 20180907 |

---

2018-12-13| UME| Utility model registered|Effective date: 20181213 |

优先权:

---

申请号 | 申请日 | 专利标题

---

EP14169754.0A|EP2946766B1|2014-05-23|2014-05-23|Liquid pharmaceutical composition|

---

EP14169754|2014-05-23|

---